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Disruption in normal apoptosis can contribute to the onset of different 
disease states, including cancer.  Additionally, many clinically relevant cancer 
drugs are effective for their ability to initiate the apoptotic process.  Most often 
this involves the activation the mitochondria-mediated pathway, but the 
development of specific agents that can activate the receptor-mediated 
pathway is of increasing interest.  Within the existing paradigm of 
mitochondria-mediated apoptosis, which is activated by intracellular stress, 
such as DNA damage and cytoskeletal disruption, the pathway is thought to 
proceed in a linear fashion.  Mitochondria outer membrane permeabilization 
(MOMP) and the release of intermembrane space proteins, such as 
cytochrome c, are early events during mitochondria-mediated apoptotic 
signaling.  In addition, Apaf-1 is a critical component of the mitochondrial 
pathway and is generally thought to reside downstream of MOMP.    
My dissertation investigates the molecular requirements essential for 
MOMP during stress-induced and receptor-mediated apoptosis.  To do so, I 
used distinct clones of Jurkat T-lymphocytes in which the mitochondria-
mediated pathway had been inhibited at three different steps.  First, cells 
stably overexpressed Bcl-2/Bcl-xL to inhibit the activation of Bak, a key 
regulator of MOMP.  Second, cells were stably depleted of Apaf-1 to inhibit 
the activation of the initiator death protease caspase-9.  Finally, cells were 
stably overexpressed with full-length X-linked inhibitor of apoptosis protein 
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(XIAP) to indirectly inhibit activated death proteases caspase-9, -7 and -3.  
Cells were stably overexpressed with BIR1/BIR2 domains of XIAP to 
indirectly inhibit activated effector death proteases caspase-3 and -7. 
The first aim investigated the molecular requirements necessary for 
Bak activation.   Apaf-1-deficient cells and cells overexpressing full-length 
XIAP or the BIR1/BIR2 domains of XIAP inhibited mitochondrial apoptotic 
events.   The data obtained suggest that caspase-mediated positive 
amplification of initial mitochondrial changes can determine the threshold for 
irreversible activation of the intrinsic apoptotic pathway.    
As mentioned previously, a second apoptotic pathway is called the 
receptor-mediated pathway.  In some cell types (type II), the mitochondria-
mediated pathway is also required for cell death upon stimulation of the 
receptor-mediated pathway.  In the second aim, I used type II Jurkat clones in 
which the mitochondrial apoptotic pathway had been inhibited at the different 
steps to investigate the molecular requirements necessary for Fas-mediated 
apoptosis.  Apaf-1-deficient type II Jurkat cells were sensitive to anti-Fas.  
Inhibiting downstream caspase activation by overexpression of the BIR1/BIR2 
domains of XIAP decreased all anti-Fas-induced apoptotic changes.  
Combined, my findings strongly suggest that Fas-mediated activation of 
executioner caspases and induction of apoptosis does not depend on 
apoptosome-mediated caspase-9 activation in prototypical type II cells.   
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In the third aim, mitochondrial apoptotic events were examined after 
prolonged treatment with etoposide (> 6 h).  Although Apaf-1-deficient cells 
were resistant to etoposide, total cellular cytochrome c and Smac were 
decreased after 24 h of incubation.  The Apaf-1-deficient cells displayed 
subtle biochemical markers of autophagy.  Interestingly, inhibition of the 26S 
proteasome by co-treatment of Apaf-1-deficient cells with bortezomib or 
MG132 led to the robust retention of total cellular cytochrome c and Smac.  
Combined, these data suggest that proteasomal degradation, and, to a lesser 
extent, autophagy, is responsible for the loss of intracellular cytochrome c and 
Smac in the Apaf-1-deficient cells incubated with etoposide over extended 
time periods. 
 x
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Apoptotic cell death is important for normal embryonic development 
and for tissue homeostasis in the adult organism.  Cells can initiate apoptosis 
for a multitude of reasons including because a cell has sustained irreversible 
DNA damage, chromosomal instability, oncogene activation, anoikis, kinase 
inhibition, microtubule perturbation (Letai, 2009; Letai et al., 2002), or 
because the body’s immune system recognizes the cell as infected or 
abnormal.  As a result, any disruption in normal apoptosis can contribute to 
the onset of different disease states.  With diseases such as Parkinson's, 
AIDS, myocardial infarction, and Type I diabetes, too much cell death has 
occurred, whereas with diseases such as rheumatoid arthritis, polycythemia 
vera, and cancer, the body does not have enough cell death, see Figure 1 
(Fadeel et al., 1999; Fesik, 2005; Riedl and Shi, 2004; Thompson, 1995). 
Cancer is a prevalent chronic disease that touches many Americans in 
economic and social ways. Economic burdens range from the cost of cancer 
preventative measures, treatment, and screenings, to the loss of productivity 
of the cancer patients and their families while they battle the disease.  















• Type I diabetes
 
Figure 1. Cell Death in Human Disease.   
 
This schematic illustrates the importance of a balance between the rate of cell 
death and cell proliferation.  When there is too much cell death, it leads to cell 
demise and has been implicated in many diseases such as Type I diabetes.  
When there is too little cell death, it can lead to cell accumulation and this has 
been implicated in diseases such as cancer. AIDS, acquired immune 
deficiency syndrome; SLE, systemic lupus erythematosus.  Adapted from 
(Robertson et al., 2002).
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cases of cancer will be diagnosed in the year 2009 and an estimated 1,500 
people will die every day of cancer in the United States. 
Cancer arises from too much cellular proliferation and/or too little 
apoptosis.  Apoptosis is involved in many aspects of cancer.  One mechanism 
by which the body can evade cancer is for the immune system to recognize 
an aberrant or precancerous cell and trigger it to undergo apoptosis.  During 
the transformation of a normal cell to a malignant cell, the transforming cell 
often encounters many pro-apoptotic changes.  Such triggers that would 
normally promote apoptosis induction include chromosomal instability, 
oncogene activation, and cellular detachment.  These triggers need to be 
overcome and apoptosis needs to be prevented for the cell to become 
malignant (Green and Evan, 2002; Hanahan and Weinberg, 2000).  The 
malignant cell can overcome apoptosis either by decreasing the expression of 
pro-apoptotic proteins or increasing the expression of anti-apoptotic proteins 
(Letai, 2008).  In fact, avoidance of apoptosis is one of the six recognized 
acquired capabilities of cancer cells (Hanahan and Weinberg, 2000).  
Additionally, many clinically important cancer drugs are effective for their 
ability to initiate the apoptotic process, most often by activating the 
mitochondrial apoptotic pathway.  Importantly, disruptions in the control of the 
mitochondrial apoptotic pathway can contribute to the resistance of cancer 
cells to antineoplastic therapy (Green and Kroemer, 2005; Johnstone et al., 
2002).  
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Currently, the majority of the literature suggests that mitochondria-
mediated apoptosis is a linear pathway.  Specifically, mitochondrial outer 
membrane permeabilization (MOMP) and the release of cytochrome c are 
widely thought to occur upstream and independently of caspases in an all-or-
none manner (Chipuk et al., 2006).  However, several lines of recent 
evidence, including data from our laboratory (Franklin and Robertson, 2007; 
Shawgo et al., 2008; Shelton et al., 2009), are in conflict with such a rigid 
view of the mitochondria-mediated apoptotic pathway.  The results of my 
dissertation project have increased our knowledge of the molecular 
requirements necessary to irreversibly commit a cell to undergo apoptosis in 
response to genotoxic injury.  Specifically, I show that signaling events 
generally thought to lie downstream of MOMP are, in fact, required to 
positively amplify cytochrome c release in response to genotoxic stress.  This 
contribution is significant because it provides important new basic information 
about cellular life-death decisions that could be key for the development of 
more rational approaches to therapy.  Such new information of molecular 
pathways governing apoptosis induced by genotoxic stimuli and the 
mechanisms cells may use to evade cell death is expected to facilitate a more 
targeted approach to drug design.  Apart from my studies on genotoxic 
stress-induced apoptosis, I also provide new insights on the molecular 





Apoptosis was first described in 1972 (Kerr et al., 1972) and the field 
has had many advances in the past 10-15 years.   Apoptosis is a highly 
conserved mechanism of cell death that occurs in most, if not all, tissue types 
of multicellular organisms (Figure 2) (Brunelle and Letai, 2009).  As 
mentioned previously, apoptosis is important in various pathological states, as 
well as during normal cellular processes, such as development, cellular 
differentiation, and maintaining tissue homeostasis.  During development, 
apoptosis is an important process that is needed to eliminate the excess 
tissue that is initially produced, for example, the skin between digits (Meier et 
al., 2000).  In order to maintain tissue homeostasis, apoptosis can eliminate 
older cells when new cells have been produced.  The lining of the digestive 
tract, hair cells, and hematopoietic cells are examples of cell types that have 
a fast turnover rate and where apoptosis is very important.   
There are many regulators of apoptosis (Figure 3).  They can be 
divided up into proteins that (i) prevent apoptosis (anti-apoptotic) and (ii) 
those that help to promote apoptosis (pro-apoptotic).  The anti-apoptotic 
members can be further subdivided into two groups: (i) those proteins that 
help to keep the mitochondrial outer membrane intact; and (ii) those that 
prevent the activation of a family of death proteases known as caspases.  
Likewise, the pro-apoptotic members can be further subdivided into three  
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Figure 2. Conservation of Core Cell Death Genes Between C. elegans 
and Humans. 
A lot of what we know about mammalian apoptosis is due to the research 
conducted by Robert Horwitz in the nematode C. elegans.  He discovered 
three core death proteins promoting apoptosis: EGL-1, CED-4 and CED-3.  
The mammalian homologs of these proteins are BH3-only proteins, Apaf-1, 
and caspases, respectively.  He also discovered the anti-apoptotic protein 
CED-9, whose mammalian homolog is Bcl-2.  The main difference between 
apoptosis in C. elegans and humans is that while CED-9 can bind directly to 
CED-4 to prevent the activation of caspases, the CED-9 homolog Bcl-2 
cannot directly bind to the CED-4 homolog Apaf-1.  Rather, Bcl-2 prevents the 
release of pro-apoptotic proteins into cytosol, such as cytochrome c, which is 
required for activation of caspases by Apaf-1.  EGL-1, egg laying defect; CED, 
cell death abnormalities; WAH-1, worm AIF homolog;  CPS-6, CED-3 
protease suppressor;  BH3, Bcl-2 homology domain 3; Bcl-2, B-cell 
lymphoma 2; Cyt. c, cytochrome c; Apaf-1, Apoptotic protease activating 
































Figure 3. Characterization of Apoptotic Players. 
Proteins involved in apoptosis can be divided up into proteins that prevent 
apoptosis and those that promote apoptosis.  Anti-apoptotic proteins can be 
furthered divided into proteins that prevent mitochondrial outer membrane 
permeablization (MOMP) (e.g. Bcl-2, Bcl-xL, and Mcl-1) and those proteins 
that prevent caspase activation (e.g. inhibitors of apoptosis). Pro-apoptotic 
proteins can be divided into three categories: (i) Proteins that help MOMP 
(e.g. Bid, Bim, Bax, and Bak), (ii) Pro-apoptotic proteins that are released 
from the mitochondria (e.g. cytochrome c, Smac, and Omi) and (iii) Caspases.   
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groups: (i) those that help to permeablize the mitochondrial outer membrane; 
(ii) pro-apoptotic factors that are released from the mitochondrial 
intermembrane space; and (iii) caspases.  Each of these groups and 
subgroups will be discussed in greater detail for the remainder of this chapter. 
 
1.2.1 B-Cell Lymphoma 2 (Bcl-2) Family Proteins 
 
One of the regulators of mitochondrial outer membrane integrity is the 
Bcl-2 family of proteins (Danial and Korsmeyer, 2004).  The Bcl-2 family is 
important in both preventing and promoting MOMP.    The founding member 
of this family of proteins was Bcl-2, which stands for B-cell lymphoma 2.  Bcl-
2 was first described as an oncogene seen in follicular lymphoma with a 
(t14:18) chromosomal translocation (Tsujimoto et al., 1984).  The 
translocation put the promoter region of the immunoglobulin heavy chain in 
front of Bcl-2 gene to drive an increased expression of Bcl-2 protein.  It was 
determined that increased expression of Bcl-2 did not increase proliferation.   
Subsequently, it was found to have the ability to prevent cell death (Vaux et 
al., 1988).  The Bcl-2 family of proteins has now grown to contain about 20 
members (Jin and El-Deiry, 2005).  For a list of well characterized Bcl-2 
proteins see Table 1.  The Bcl-2 family members share one to four Bcl-2 
homology (BH) domains.  The BH3 domain, present in all Bcl-2 family 
members, is important for protein-protein interactions as well as the pro- 
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BH3 – Bcl-2 homology domain 3 
Bcl-2 – B-cell lymphoma 2 
Bad – Bcl-2 associated death promoter 
Bid – BH3 interacting domain 
Bak – Bcl-2 antagonist/killer 1 
Bcl-xL – Bcl-2 like 1 
Bik – Bcl-2 interacting killer 
Bim – Bcl-2 interacting mediator of cell death  
Bax – Bcl-2 associated X protein 
Bcl-w – Bcl-2 like 2 
BHIP3 – Bcl-2/adenovirus E1B 19kDa interacting protein 3  
Puma – p53 upregulated modulator of apoptosis 
Bok – Bcl-2 related ovarian killer 
Bfl-1 – Bcl-2 related protein A1 
Bmf – Bcl-2 modifying factor 
Mcl-1 – Myeloid cell leukemia sequence 1 
Blk – B lymphoid tyrosine kinase 
Hrk – Harakiri, Bcl-2 interacting protein  
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apoptotic effects that some members possess (Cheng et al., 2001; Wei et al., 
2001; Zong et al., 2001).  The BH4 domain exhibits anti-apoptotic effects, and 
is only present in the anti-apoptotic proteins. The Bcl-2 family of proteins can 
be broken down into two separate categories: (i) those proteins that prevent 
apoptosis and are grouped as anti-apoptotic; and (ii) those proteins that 
promote cell death and are categorized as pro-apoptotic (Chittenden et al., 
1995; Danial and Korsmeyer, 2004).    
 
1.2.2 Bcl-2 Anti-Apoptotic Proteins 
 
 The anti-apoptotic Bcl-2 sub-family of proteins that prevents apoptosis 
includes Bcl-2, Bcl-2-like 1 (Bcl-xL), Bcl-2-like 2 (Bcl-w), BF-1, A1 and Myeloid 
cell leukemia-1 (Mcl-1).  Anti-apoptotic Bcl-2 family members are primarily 
located on the mitochondrial outer membrane.  They help to preserve the 
integrity of the mitochondrial outer membrane by preventing permeabilization.  
One way in which this occurs is that the BH3 domain of an anti-apoptotic Bcl-
2 family protein binds to the BH3 domain of the pro-apoptotic Bcl-2 family 
members to inhibit their pro-apoptotic activity.  However, not all anti-apoptotic 
Bcl-2 family members will bind to all pro-apoptotic Bcl-2 family members.  For 
example, Bcl-2 has preference for binding BH3-interacting-domain (Bid) over 
Bcl-2-interacting mediator of cell death (Bim), while Mcl-1 prefers to bind to 
Bcl-2 interacting killer (Bik) and Noxa over binding to Bcl-2-associated death 
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promoter (Bad) (Certo et al., 2006).  One way cancer cells overcome 
apoptosis is by overexpressing one or more of the Bcl-2 anti-apoptotic family 
members (Sentman et al., 1991; Strasser et al., 1991). 
 
1.2.3 Bcl-2 Pro-Apoptotic Proteins  
 
The pro-apoptotic Bcl-2 family proteins work together to permeablize 
the outer mitochondrial membrane.  MOMP allows for pro-apoptotic factors 
(cytochrome c, second mitochondrial activator caspases (Smac) and Omi) 
held within the intermembrane space of the mitochondria to be released into 
the cytosol  (Cartron et al., 2004; Desagher et al., 1999; Kuwana et al., 2005; 
Kuwana et al., 2002; Luo et al., 1998; Marani et al., 2002) where they function 
to promote caspase activation.  Pro-apoptotic Bcl-2 family members can be 
further separated into two groups depending on the number of BH domains 
they contain: (i) proteins with BH domains one through three characterized as 
mulitdomain; and (ii) proteins with only the third BH domain characterized as 
BH3-only proteins.  
 
1.2.3.1 Bcl-2 Pro-Apoptotic Proteins – Multidomain  
 
Proteins with BH domains one through three are called multidomain 
Bcl-2 family members (also known as BH123 proteins).  The multidomain Bcl-
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2 sub-family has three members: Bcl-2-associated X protein (Bax), Bcl-2-
antagonist/killer 1(Bak) and Bcl-2-related ovarian killer (Bok).  Bax and Bak 
are widely distributed throughout different tissue types, while Bok is found 
only in some reproductive tissues.  I will focus on Bax and Bak.  Under non-
apoptotic conditions, Bax (cytosolic) and Bak (mitochondrial) exist as 
monomers.  However, under apoptotic conditions Bax and Bak will be 
induced to change their conformation allowing them to homo-oligomerize to 
form a pore on the outer mitochondrial membrane. It is this pore that allows 
for the pro-apoptotic factors to be released into the cytosol (Cheng et al., 
2001; Wei et al., 2001).  It is thought that Bax stays in the cytosol due to its C-
terminal membrane anchor that is normally hidden.  Once Bax undergoes a 
conformational change, the C-terminal membrane anchor is exposed to allow 
for its translocation and homo-oligomerization (Suzuki et al., 2000) (Figure 4).  
One way that cancer cells overcome apoptosis is through decreasing the 
expression of Bax and Bak.  Both multidomain Bcl-2 family members need to 
be eliminated before the malignant cell can inhibit apoptosis (Certo et al., 
2006).  
 
1.2.3.2 Pro-Apoptotic Proteins – BH3 Only  
 
The other pro-apoptotic Bcl-2 proteins only contain the third BH 















Figure 4. Mechanisms of Regulation of the Bcl-2 Family Members on the 
Outer Mitochondrial Membrane.  
After an internal apoptotic signal a BH3-only-senstizer protein (e.g. 
Bad) will displace the anti-apoptotic Bcl-2 family members (Bcl-2 or Bcl-xL) 
from any activated BH3-only-activator (e.g. Bid) proteins.  The BH3-only-
activator proteins will then change the conformation of a Bcl-2-multidomain 
protein (e.g. Bax or Bak).  This allows for the homo-oligomerization of the 
multidomain Bcl-2 family proteins.  Mitochondrial intermembrane space 
proteins (pro-apoptotic proteins) can be released into the cytosol to activate 
caspases. Bad, Bcl-2 associated death promoter; Bak, Bcl-2 antagonist/killer 
1; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, Bcl-2 like 
1; IAP, Inhibitors of apoptosis; Bid, BH3 interacting domain.
 15
thought to occur by one of two mechanisms.  According to the first model, 
BH3-only proteins are categorized into two groups: (i) activators (also known 
as inducers); and (ii) sensitizers (also known as inhibitors or derepressors).  
BH3-only activators that induce multidomain Bcl-2 family members include 
Bid and Bim (Cartron et al., 2004; Desagher et al., 1999; Kuwana et al., 2005; 
Kuwana et al., 2002; Luo et al., 1998; Marani et al., 2002).  The BH3-only 
sensitizers are proteins that inhibit the anti-apoptotic proteins and some 
include Bad, Harakiri, Bcl-2 interacting protein (Hrk), Bcl-2 modifying factor 
(BMF), and Noxa.  Protein 53 (p53)-upregulated modulator of apoptosis 
(Puma) has been labeled as both an activator and a sensitizer (Letai, 2009).  
For example, Certo et al. (2006) categorizes Puma as a sensitizer, not an 
activator, because their studies showed a Puma BH3 domain lacked the 
ability to activate Bax and/or Bak.  However, Kim et al. (2006), demonstrate 
that full length Puma is equal in its ability to activate Bax as Bim and Bid. 
BH3-only activator proteins function to promote apoptosis by changing 
the conformation of the pro-apoptotic Bcl-2 multidomain family members 
(Bax/Bak), namely from monomeric to homo-oligomeric.  This leads to MOMP 
induction and the release of pro-apoptotic factors into the cytosol.  BH3-only 
activators have a line of regulation all of their own.  Most BH3-only activator 
proteins are constitutively present in the cytosol in inactive forms.  For 
example, under non-apoptotic conditions Bid is located in the cytosol in an 
inactivated form (full-length Bid).  To be able to induce a conformational 
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change and thereby activate Bax/Bak, Bid first has to be cleaved to its 
truncated form (tBid) (Figure 4).  While Bim is also located in the cytosol, it is 
maintained in an inactive state, at least in part, by binding to cytoskeleton 
(Puthalakath et al., 1999).  Bcl-2 anti-apoptotic members can sequester the 
activated BH3-only activators (Bid and Bim) and prevent them from changing 
the conformation of Bax/Bak.   
BH3-only sensitizer proteins (Bad and Bik) can also help facilitate 
MOMP.  BH3-only sensitizer proteins can boot a BH3-only activator protein 
off of an anti-apoptotic Bcl-2 family member (Bcl-2, Bcl-xL).  This allows the 
newly released BH3-only activator proteins (Bid or Bim) to change the 
confirmation of Bax/Bak (Kim et al., 2006a; Letai et al., 2002).  BH3-only 
sensitizers also have another line of regulation.  They either have to be 
activated or up-regulated.  For example, Bad has to be dephosphorylated to 
become activated (Zha et al., 1996).  Bik on the other hand is up-regulated in 
response to an apoptotic stimulus (Hur et al., 2006).  Overall, it is often the 
relative number of pro-apoptotic Bcl-2 family members compared to the 
number of anti-apoptotic Bcl-2 family members that either allow MOMP or 
prevent MOMP from occurring (Brunelle and Letai, 2009).    
 There is a second model that describes how pro-apoptotic Bcl-2 family 
of proteins promotes MOMP.  This model does not distinguish between BH3-
only sensitizers (Bad and Bik) and activators (Bid and Bim) but rather how 
selective the different BH3-only proteins are for the anti-apoptotic family  
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members (Bcl-2, Bcl-xL).  For example, Bim and Puma can bind and inhibit all 
anti-apoptotic proteins but Bad and Noxa can only bind a few (i.e. Noxa can 
bind Mcl-1 and A1) (Youle and Strasser, 2008).  In this model, the BH3-only 
members do not directly bind Bcl-2 multidomain proteins (Bax and Bak).  
Under non-apoptotic conditions, Bax and/or Bak are held in their inactive 
forms by the anti-apoptotic Bcl-2 proteins.  Originally it was suggested that 
BH3-only proteins bind to Bcl-2 anti-apoptotic proteins to change their 
conformation thus preventing their ability to bind to Bax or Bak (Strasser et al., 
2000).  One way this model has tried to refute the other model was through 
the use of binding assays and co-immunoprecipitating studies.  They 
demonstrate through the use of BH3-only peptides that they indirectly activate 
Bcl-2 multidomain proteins (Bax and Bak) by binding and inhibiting the anti-
apoptotic Bcl-2 family proteins and not binding Bax and Bak.  They go on to 
show using full length Bcl-2 that BH3-only proteins (Bid and Bim) do not co-
immunoprecipitate with Bax (Chen et al., 2005; Willis et al., 2007).  Willis et al. 
(2007) go on to demonstrate that “Bcl-2 BH3-only activator proteins” (Bid/Bim) 
double knockout mice can still undergo apoptosis with various apoptotic 
stimuli.  Their data suggest that “Bcl-2 BH3-only activator proteins” are not 
needed to change the conformation of Bax and/or Bak (Willis et al., 2007).   
The two conflicting views indicate that the precise biochemical mechanism to 
activate Bax and Bak is yet to be determined.              
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1.2.4 Pro-Apoptotic Factors Released From the Mitochondria  
 
 As alluded to earlier, once MOMP has occurred, pro-apoptotic factors 
are released from the intermembrane space of the mitochondria, including 
cytochrome c (Liu et al., 1996), Smac (Du et al., 2000), Omi, endonuclease G 
(Li et al., 2001), and apoptosis inducing factor (AIF) into the cytosol (Susin et 
al., 1999).  These proteins are thought to move across the outer mitochondrial 
membrane by going through the pore that is produced by multidomain Bcl-2 
family members (Bax or Bak).  Cytochrome c, Smac and Omi all help to 
activate caspases while the other proteins promote apoptosis independently 
of caspases.   I will be focusing on some of the pro-apoptotic factors 
(cytochrome c, Smac and Omi). Cytochrome c directly activates caspases, 
whereas Smac and Omi help to activate caspases indirectly (Figure 5).   
 
1.2.4.1 Pro-Apoptotic Factors Released From the Mitochondria – Cytochrome 
c 
Cytochrome c helps to activate caspases by inducing the formation of 
an activating platform for the initiator caspase-9 called the apoptosome 
complex.  Once cytochrome c is in the cytosol, it will bind the initiator 
caspase-9’s adaptor molecule apoptotic protease activating factor 1 (Apaf-1).  
Apaf-1 is a 130 kDa protein that contains three domains: (i) caspase  
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Figure 5. Role of Pro-Apoptotic Proteins (Cytochrome c, Smac, and Omi) 
that Are Released into the Cytosol from the Intermembrane Space of 
Mitochondria. 
Pro-apoptotic factors released from the mitochondria after an apoptotic 
stimulus include cytochrome c, Smac, and Omi.  These pro-apoptotic factors 
help to activate caspases in different ways.  Cytochrome c helps to activate 
caspase-9 by allowing for Apaf-1 to homo-oligomerize and form the 
apoptosome complex.  The apoptosome will then mediate caspase-9 
activation.  Smac helps to activate caspases by displacing inhibitors of 
apoptosis (IAPs) from activated caspase-3, -7, or -9.  Omi will help to activate 
caspases by causing IAPs to be degraded and released from any activated 
caspases. Apaf-1, apoptotic protease activating factor 1; Cyt c, cytochrome c; 
casp, caspase; IAP, inhibitors of apoptosis; Smac, Second mitochondrial 













































recruitment domain (CARD) at the N-terminal; (ii) nucleotide binding domain; 
and (iii) WD-40 repeats at the C-terminal (Zou et al., 1999). Under non-
apoptotic conditions, Apaf-1 resides in the cytosol as an inactive monomer 
and its activation involves heptamerization.  It is thought that when Apaf-1 is 
an inactive monomer, the C-terminal domain covers the N-terminal CARD 
domain and prevents its heptamerization.  When cytochrome c is able to bind 
to the C-terminal domain of Apaf-1, Apaf-1 can change its conformation.  
Specifically, Apaf-1 can linearize and dATP hydrolysis occurs.  Next, dATP is 
exchanged for the dADP (Kim et al., 2005).  Subsequently, Apaf-1 
oligomerizes to form a seven (heptamer) spoke wheel known as the 
apoptosome complex.  The apoptosome, in turn, recruits up to seven initiator 
pro-caspase-9 proteins at one time (Acehan et al., 2002; Srinivasula et al., 
1998).  Due to the orientation of the apoptosome, the CARD domain of Apaf-1 
will be available for interaction with the CARD domain of pro-caspase-9.  This 
permits the autoactivation of pro-caspase-9 (Boatright et al., 2003; Chao et 
al., 2005; Pop et al., 2006; Rodriguez and Lazebnik, 1999; Shiozaki et al., 
2002).   
Cytochrome c also has a non-apoptotic function.  Cytochrome c is 
transcribed by a nuclear gene and then translated in the cytosol as the 
apocytochrome c protein.  Apocytochrome c then translocates to the 
mitochondrial intermembrane space where a heme group is covalently 
attached by cytochrome c heme lyase to form holocytochrome c.  It is the 
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heme group that allows it to be a redox intermediate and shuttle electrons 
from complex III to complex IV of the electron transport system to help 
generate ATP (Ow et al., 2008). 
  
1.2.4.2 Pro-Apoptotic Factors Released From the Mitochondria – Inhibitor of 
Apoptosis Protein (IAP) Neutralizers 
 
The other two known pro-apoptotic factors released from the 
mitochondrial intermembrane space that help activate caspases include 
Smac and Omi.  Smac and Omi help to activate caspases indirectly by 
inhibiting IAPs, most notably X-linked inhibitor of apoptosis (XIAP).  Under 
normal circumstances, IAPs serve a protective role by binding any partially 
cleaved/active caspase-3, -7, or -9.  Preventing caspase full catalytic 
activation also prevents apoptotic cell death.  In this regard, Smac and Omi 
released into the cytosol can help overcome this inhibition, if necessary 
(Figure 5).   
Smac is also known as direct IAP-binding protein with low pI (Diablo).  
After MOMP, Smac is released into the cytosol and homo-dimerizes.  The 
dimerization of Smac allows it to bind to IAPs and sequester them away from 
active caspases (Wu et al., 2000).  Specifically, Smac binds XIAP within 
XIAP’s Baculovirus IAP repeat domain known as Baculovirus IAP repeat 
(BIR) 3.  XIAPs will be expanded upon later (Takahashi et al., 1998).   
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 Omi, a serine protease, is also known as high temperature requirement 
protein A2 (Htr2a).  Omi inhibits IAPs slightly differently from Smac, which 
sequesters IAPs.  Omi actually degrades IAPs and thus prevents them from 
binding to activated caspases (Yang et al., 2003).  Omi is also important in 
degraded of cytoskeleton proteins and cellular substrates that caspases do 
not cleave (Vande Walle et al., 2007). It has been suggested that it is at the 
apoptosome with activated caspase-9 where caspase-3 and -7 are activated.  
It is also at the apoptosome  where IAPs bind to inhibit caspase-3, -7, -9 and 




 Another major pro-apoptotic player is the caspase family.  Caspases 
(cysteine proteases that cleave after aspartate residues) were first described 
in 1992 and 1993 by two different groups.  One group described the human 
protease for activated interleukin 1β, caspase-1 (Cerretti et al., 1992; 
Thornberry et al., 1992), and the other group described the protein product of 
the cell death abnormalities (CED) 3 gene (Yuan et al., 1993).  Currently, 
there are 13 known mammalian caspases.  Caspase-2, -3, -6, -7, -8, -9, -10 
and -12 are involved in apoptosis.  However, full length caspase-12 is only 
found in a small population of people since normally it is translated as a 
truncated protein. Caspase-1, -4, -5, -11, and -14  are most often associated 
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with activities other than apoptosis, such as inflammation (caspase-4, -5), 
innate immunity (caspase-1), and skin cell development (caspase-14) (Yi and 
Yuan, 2009).    Caspases are primarily responsible for the biochemical and 
morphological changes that occur in the cell during apoptosis.   
The caspases involved in apoptosis exist in cells as catalytically 
inactive zymogens known as pro-caspases.  Pro-caspases are thought to be 
activated either through dimerization, allosteric regulation, or cleavage.  
Apoptotic caspases are a group of proteases that target a range of substrates.  
These substrates include pro-caspases, structural proteins, and cellular DNA 
proteins (Cohen, 1997; Jin and El-Deiry, 2005).  Caspases have three 
subunits: (i) a prodomain, (ii) large subunit and (iii) small subunit.  Pro-
caspases are typically cleaved after their two Asp-X sites (Thornberry et al., 
1997) to produce a long and short subunit.  The large subunit contains the 
conserved catalytic site QACXG (Q, glutamine; A, alanine; C, cysteine; X, any 
amino acid; G, glycine) (Figure 6). The apoptotic caspases are commonly 
divided into two groups: initiator caspases and effector caspases.  The length 




























Figure 6. Caspase Classification and Activation.  
Caspases are constitutively expressed in the cytosol as inactive aspartate 
proteases known as procaspases.  Caspases can be divided into two groups: 
(i) Initiator caspases and (ii) Effector caspases.  Initiator caspases are 
activated with the help of adaptor proteins, such as Apaf-1 for caspase-9 and 
FADD for caspase-8.  Effector caspases require proteolysis and then 
dimerization for activation.  Once effector caspases are activated they are 
able to cleave up to 1,000 cellular substrates to dismantle the cell. Asp, 
aspartate; Casp, caspase; Apaf-1, apoptotic protease activating factor 1; 
FADD, fas associated death domain; X, any amino acid.
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1.2.5.1 Initiator Caspases 
 
 The initiator pro-caspase starts the caspase cascade and includes 
caspases-8, -9, -10 and possibly caspase-2.  Initiator caspases have long 
prodomains that either have a death effector domain (DED) or CARD.  
Activation of initiator caspases is thought to occur by one of two mechanisms.  
According to the first model, adaptor proteins will allow for initiator caspases 
to dimerize with either their DED or CARD domains.   The aided dimerization 
allows for the activation of the initiator caspases (Boatright et al., 2003; Pop et 
al., 2006).  Caspase-8 and -10 are both important for the extrinsic pathway.  
Their adaptor molecules are fas-associated protein with death domain 
(FADD) and tumor necrosis factor receptor (TNFR)-associated death domain 
(TRADD).  Pro-caspase-8 (57/55 kDa) can autocleave itself to produce 
p43/41 fragments.  Caspase-9 is important for the intrinsic pathway, and its 
adaptor molecule is Apaf-1.  Pro-caspase-9 (48 kDa) can autocleave itself to 
generate a p35 fragment.  It can also be cleaved by activated caspase-3 to 
generate a p37 fragment.  Caspase-2 has been suggested to be the initiator 
caspase for heat shock due to its long pro-domain (Tu et al., 2006).  Some 
evidence suggests that caspase-2’s adaptor molecule is Rip-associated ICH-
1 homologous protein with death domain (RAIDD).  Once activated, initiator 
caspases will cleave and thereby activate effector caspases to cause cell 
death.  
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The second model to describe how initiator caspases become 
activated involves allosteric modification.  One argument against the 
dimerization model is that there are seven spokes in the apoptosome and 3 
adaptor/death receptors in the death inducing signaling complex (DISC) 
(Chao et al., 2005).  For example, after apoptosome formation when pro-
caspase-9 binds to the apoptosome, pro-caspase-9 undergoes a 
conformational change to allow for its activation (Chao et al., 2005; Rodriguez 
and Lazebnik, 1999; Shiozaki et al., 2002).  This conformational change has 
been suggested to change the active site of the initiator caspases to increase 
their activity (Chao et al., 2005).  Recently Malladi et al. (2009) demonstrated 
that pro-caspase-9, has a higher affinity for the apoptosome than does 
activated caspase-9, suggesting that once activated caspase-9 dissociates 
from the apoptosome complex to allow another pro-caspase-9 molecule to 
bind.  Secondly, they demonstrate that caspase-3 is cleaved and activated at 
the apoptosome.  They suggest that the amount of pro-caspase-9 present in 
the cell acts as a molecular clock to determine how long the apoptosome will 
be formed (Malladi et al., 2009).  Even though there are data that support the 
allosteric activation model, there are currently not enough data to contradict 
all of the data that support the dimerization model. Chao et al. even suggest 
that both models might exist—allosteric for caspase-9 and dimerization for the 
other initiator caspases  (Chao et al., 2005). 
 
 28
1.2.5.2 Effector Caspases 
 
Effector caspases have short prodomains and include caspase-3, -6, 
and -7.  Effector caspases are usually more abundant than the initiator 
caspases.  Unlike the initiator caspases that require dimerization for activation, 
effector caspases require cleavage and then dimerization of the cleaved 
fragments.  Some even suggest that effector caspases, specifically caspase-7, 
exist in their pro-forms as homodimers and cleavage increases their catalytic 
activity (Chai et al., 2001; Riedl et al., 2001a).  The effector caspases will then 
proteolytically degrade the cellular contents.  Caspase-3 has been recognized 
as the vital effector caspase (Jin and El-Deiry, 2005).   Pro-caspase-3 (32 
kDa) is cleaved initially by caspase-8 and/or -9 to form a p20 and a p12 
fragment.  The caspase-3 p20 fragment has only enough catalytic activity to 
cleave itself into the p19 and then p17 fragment.  It is caspase-3’s p17/p12 
that is the fully active caspase.  The p17/p12 dimer can go on to cleave over 
1,000 endogenous death substrates (Fuentes-Prior and Salvesen, 2004).  It is 
activity of caspases that is directly or indirectly responsible for the classical 
morphological and biochemical characteristics of an apoptotic cell such as 
condensed nuclei, membrane blebbing, DNA laddering, and the exposure of 
phosphatidylserine on the outer plasma membrane (Brunelle and Letai, 2009; 





As alluded to previously, IAPs are a family of proteins that can prevent 
the accidental activation of caspases by binding to partially active caspase-3, 
-7, and -9 to prevent their full catalytic activation.  In this way, IAPs can 
prevent apoptosis by preventing caspase activity.  The original IAP was 
discovered from a baculovirus that infected insect cells.  This gene was 
determined to have the ability to inhibit apoptosis (Crook et al., 1993). 
Currently, there are eight proteins identified as IAPs, including cIAP1, cIAP2, 
XIAP, Survivin, and NAIP.  Human IAP members share a 70 amino-acid BIR 
domain that contains the sequence CX2CX16HX6C (C, cysteine; H, histidine, X, 
any amino acid). It has been suggested that another way cancer cells have 
overcome apoptosis is by overexpressing one of the IAPs.  IAPs have been 
observed to be highly expressed in several neoplasms (Srinivasula and 
Ashwell, 2008).    
IAPs can have one or multiple BIR domains (Sun et al., 1999a).  IAPs 
frequently have other functional domains that include RING and CARD 
domains (Hinds et al., 1999; Sun et al., 1999a; Verdecia et al., 2000).  The 
most studied and understood IAP is XIAP which has three BIR domains and a 
RING domain (Jin and El-Deiry, 2005).  Typically BIR2 and BIR3 are involved 
in binding to caspases or apoptosis regulatory molecules (i.e. Smac and Omi).   
It is the region around XIAP’s third BIR domain (Takahashi et al., 1998) that 
inhibits caspase-9 activity by binding to caspase-9’s p35 fragment (Chai et al., 
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2001; Huang et al., 2001).  The linker region around the second BIR region in 
XIAP inhibits caspase-3 and -7 (Takahashi et al., 1998) (Figure 7).  As 
mentioned before IAPs can be antagonized by mitochondrial intermembrane 
space proteins (Smac and Omi).  Smac and Omi can interact with IAP at their 
IAP-binding motifs.  The BIR2 and BIR3 on the IAP will bind to the IAP-
binding motif of Smac or Omi (Shiozaki and Shi, 2004; Srinivasula et al., 
2000). 
The only known IAP able to bind and inhibit caspase activity is XIAP 
(Eckelman and Salvesen, 2006).    The other IAPs were recently shown to 
bind only to caspase-3, -7, and -9 but were unable to inhibit their catalytic 
activity (Eckelman and Salvesen, 2006).  There is now persuasive evidence 
to suggest that IAPs’ function is more than just to inhibit apoptosis.  IAPs 
have now been implicated in a role in cell division, morphogenesis, heavy 
metal homeostasis and MAP kinase signaling (Srinivasula and Ashwell, 2008).   
 
1.2.7 Apoptotic Pathways 
 
After extensive study, it is now known that there are two main apoptotic 
pathways: (i) the intrinsic or mitochondria-mediated pathway; and (ii) the 











Figure 7. Schematic Representation of XIAP’s Domains and How They 
Inhibit Caspases. 
XIAP has three baculoviral inhibitor of apoptosis repeat (BIR) domains.  A 
region of XIAP that includes the BIR2 domain is responsible for binding to and 
inhibiting activated caspase-3 and caspase-7.  The BIR3 domain is 


















































Figure 8. Schematic Representation of the Intrinsic and Extrinsic 
Apoptotic Pathways. 
The intrinsic pathway is also known as the mitochondria-mediated pathway.  
The extrinsic pathway is also known as the receptor-mediated pathway. Cyt c, 
cytochrome c; Casp, caspase; Bid, BH3 interacting domain; tBid, truncated 
Bid; Apaf-1, apoptotic protease activating factor 1; Bak, Bcl-2 antagonist/killer 
1; Bax, Bcl-2-associated X protein; Bcl-2, B cell lymphoma 2; Bcl-xL, Bcl-2 like 
1; IAP, Inhibitors of apoptosis. 
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1.2.7.1 Apoptotic Pathways – Mitochondria-Mediated  
 
The mitochondria-mediated (intrinsic) pathway is initiated by an 
intracellular stress signal.  Internal stress signals can come from heat shock, 
growth factor deprivation, oxidative stress, oncogene activation, chromosomal 
instability, and/or DNA damage.  UV radiation or chemicals, such as 
chemotherapeutic drugs, can cause DNA damage and stimulate the 
mitochondria-mediated pathway.  Even though all mammalian cells can be 
induced to undergo apoptosis by stimulation of the intrinsic pathway, the 
sensitivity of mammalian cells differs between cell types.  For example, 
thymocytes are very sensitive to DNA damage, while fibroblasts rarely 
undergo DNA damage-induced apoptosis (Norbury and Zhivotovsky, 2004).   
 The mitochondria-mediated pathway is most often depicted as a linear 
sequence of events.  Initially, a Bcl-2 BH3-only family protein (e.g. Bim, Bid, 
Noxa, or Puma) (Kim et al., 2006a) becomes activated. Currently, the precise 
molecular link between DNA damage and activation of Bcl-2 BH3-only 
proteins is unknown.  A Bcl-2 BH3-only family member will change the 
conformation of a Bcl-2 multidomain member (Bak, Bax).  Normally, these 
proteins exist as inactive monomers located in the cytosol (Bax) or associated 
with the outer mitochondrial membrane (Bak)  (Chipuk and Green, 2006; 
Scorrano and Korsmeyer, 2003).  Bax and Bak homo-oligomerize to form a 
pore on the outer mitochondrial membrane through which the release of pro-
apoptotic factors, such as cytochrome c, Smac and Omi, occurs.  Anti-
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apoptotic Bcl-2 family proteins (Bcl-2 and Bcl-xL) reside on the mitochondrial 
outer membrane and prevent the cell from undergoing MOMP.  They exert 
their inhibitory function by binding directly to a pro-apoptotic Bcl-2 family 
member and thereby inhibit the ability of Bax/Bak to form a pore.  Cytochrome 
c facilitates the activation of the initiator pro-caspase-9 by promoting the 
formation of the apoptosome (Apaf-1, cytochrome c, dATP).  The 
apoptosome is the activating platform for pro-caspase-9.  Smac and Omi help 
activate caspases by inhibiting IAP (Yang et al., 2003).  Once caspase-9 is 
activated, it can cleave and activate effector pro-caspases, such as caspase-
3 or -7.  Activated caspase-3 can cleave and/or activate other pro-caspases, 
such as caspase-2 and -6 to dismantle the cell. 
 
1.2.7.2 Apoptotic Pathways – Receptor-Mediated 
 
The receptor-mediated (extrinsic) pathway is the other main apoptotic 
pathway.  The extrinsic pathway differs from the intrinsic pathway in that an 
initiator signal comes from outside the cell.  Also, extrinsic apoptosis can be 
either MOMP-dependent or MOMP-independent.  Activation of the receptor-
mediated pathway is not only important in eliminating infectious cells but it is 
also very important during development of the immune system by removing 
self-reactive B or T lymphocytes.  The pathway is initiated by a death signal 
binding to a death receptor.  There are three types of death ligand/death 
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receptor pathways: (i) tumor necrosis factor alpha (TNF-α) binding to tumor 
necrosis factor receptor 1 (TNF-R1); (ii) Fas ligand (FasL) binding to Fas 
receptor; and (iii) TNF related apoptosis inducing ligand (TRAIL) binding to its 
death receptor 4/5 (DR4/5) (Figure 9).  I will be focusing on the FasL/Fas 
pathway due to its implication in the pathogenesis of various malignancies 
(Jin and El-Deiry, 2005). 
The extrinsic pathway begins with an exogenous signal such as a 
death ligand binding the appropriate death receptor, followed by formation of 
the death-inducing signaling complex (DISC) (Kischkel et al., 1995).  For 
example, FasL/CD95L binds to Fas/CD95.   When a death ligand binds to its 
death receptor it causes the death receptor to trimerize.  Receptor 
trimerization then recruits the association of an adaptor molecule, such as 
FADD and TRADD (Chinnaiyan et al., 1995).   The adaptor molecule FADD 
or TRADD, in turn, recruits the initiator pro-caspase-8 proteins to bind (Muzio 
et al., 1996).  Akin to binding to the apoptosome for the activation of pro-
caspase-9 molecules, it is believed that binding to the DISC allows pro-
caspase-8 proteins to stimulate autoactivation leading to self-cleavage.  
Recruitment of FADD or TRADD can also recruit initiator pro-caspase-10 
proteins to bind to the DISC (Vincenz and Dixit, 1997).  Like caspase-9, 



























Figure 9. Death-Inducing Signaling Complexes. 
To initiate the receptor-mediated apoptotic pathway a death inducing 
signaling complex (DISC) has to form. DISC is initiated by binding of a death 
ligand (FasL) to a death receptor (Fas).   This allows for trimerization of the 
death receptor followed by recruitment of an adaptor molecule (e.g. FADD or 
TRADD), which, in turn, facilitate activation of initiator caspase-8 or caspase-
10.  Casp, caspase; DR, death receptor; TNF-α, Tumor necrosis factor alpha; 
TNF-R, Tumor necrosis factor receptor; TRADD, TNF receptor associated 
death domain; FADD, fas associated death domain.  
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           In 1998, Scaffidi and colleagues classified a cell’s apoptotic sensitivity 
to death ligands as either a type I or type II cell.  After stimulation of the 
receptor-mediated pathway by a death ligand, a type I cell relies heavily on 
caspase-8 activation at the DISC that is sufficient to cleave enough caspase-
3 to cause cell death.  That initial study identified B lymphoblastoid SKW6.4 
and a T cell line H9 as type I cells.  In contrast to type I cells, type II cells 
require the involvement of the mitochondria-mediated pathway after 
stimulation of a death receptor.  Specifically, a type II cell requires the 
induction of MOMP, due to the insufficient activation of pro-caspase-8 at the 
DISC.  Instead, caspase-8 cleaves the proapoptotic Bcl-2 BH3-only activator 
family member Bid to yield tBid (Danial and Korsmeyer, 2004; Li et al., 1998).   
tBid can then relocate to the outer mitochondrial membrane and cause Bax 
and/or Bak to undergo a conformational change followed by their homo-
oligomerization and pore formation (Luo et al., 1998).  Pore formation then 
permits the release of the pro-apoptotic factors (cytochrome c, Smac, and 
Omi).  Like in the intrinsic pathway, these pro-apoptotic factors help to 
activate caspases (Figure 8).  Characteristic type II cells include Jurkat T-
lymphocytes and leukemic lymphoid CEM cells.  The current paradigm states 
that overexpressing Bcl-2 and Bcl-xL prevent MOMP.  Therefore, 
overexpression also prevents the initiator pro-caspase-9 from being 
autoactivated at the apoptosome complex (Scaffidi et al., 1998; Scaffidi et al., 
1999) (Figure 10). 
 38
Type I Type II 
Caspase-8 activation Robust Small 
Mitochondrial 
involvement
Not necessary Thought to be 
required 




Cyt. cBid Apaf-1 Casp-9 Casp-3 DeathIntrinsic
 
Figure 10. Characterization of Type I vs Type II Cells. 
A type I cell has sufficient caspase-8 activation at the DISC to cleave and 
activate caspase-3 to cause cell death.  Also, a type I cell does not require 
the mitochondria-mediated pathway to undergo receptor-mediated apoptosis.  
A type II cell does not have sufficient caspase-8 activation at the DISC to 
activate caspase-3 directly.  Instead, a type II cell requires the recruitment of 
the mitochondria-mediated pathway (via Bid cleavage to tBid) to activate 
caspase-9.  It is widely believed that the activation of caspase-9 drives 
enough caspase-3 activation to cause cell death.  Casp, caspase; FADD, Fas 
associated death domain; DISC, death inducing signaling complex. Bid, BH3 
interacting domain; Apaf-1, apoptotic protease activating factor 1. 
 39




 As mentioned previously, within the current paradigm of genotoxic 
stress-induced apoptosis, the mitochondria-mediated apoptotic pathway is 
thought to proceed in a linear fashion.  The pathway is widely thought to 
begin with the activation of a multidomain pro-apoptotic Bcl-2 protein, such as 
Bax and Bak.  These proteins are induced to form pores in the mitochondrial 
outer membrane to permeablize it.  This results in the release of pro-apoptotic 
factors that include cytochrome c and Smac.  These pro-apoptotic factors 
promote the activation of caspase-9 within the Apaf-1 apoptosome complex.  
Active caspase-9, in turn, activates caspase-3 and -7 to execute cell death.  
Apaf-1 is a critical component of the intrinsic pathway that is generally thought 
to reside downstream of MOMP.  However, a previous study in our laboratory 
reported that Apaf-1-deficeint Jurkat T-lymphocytes do not release 
cytochrome c or lose mitochondrial membrane potential in response to the 
DNA-damaging drug etoposide (Franklin and Robertson, 2007).   
In the literature there are also some gaps in the knowledge about the 
molecular mechanisms of the mitochondria-mediated and receptor-mediated 
pathways and how these pathways interact.  According to the current 
paradigm, Jurkat T-lymphocytes are labeled as classical type II cells.  This 
means that, upon stimulation of the receptor-mediated pathway, the 
 40
mitochondria-mediated pathway must also be engaged to ensure cell demise.  
A previous study from this laboratory reported that Apaf-1-deficient Jurkat T-
lymphocytes were sensitive to anti-Fas-induced apoptosis even though they 
were insensitive to etoposide-induced apoptosis (Franklin and Robertson, 
2007).   This was surprising since type II cells are reported to require the 
mitochondria-meditated pathway but apparently did not need Apaf-1.   
Therefore, clarification was needed regarding the molecular 
requirements necessary for the release of pro-apoptotic factors from the 
mitochondria during genotoxic stress-induced apoptosis.  My central 
hypothesis is that classical mitochondrial events, such as loss of 
mitochondrial membrane potential and the release of intermembrane space 
proteins, are mediated by signaling molecules that were once thought to 
reside strictly downstream of mitochondrial changes, including, but not limited 
to, activation of pro-caspase-3 and/or pro-caspase-9, neutralization of IAPs, 
and/or Apaf-1 (Figure 11). 
 
2.2 Specific Aims 
 
Specific aim 1: To determine what classical downstream factors 
(activated caspase-9, caspase-3 or inhibition of IAPs) are required for MOMP 
to occur after treatment with DNA-damaging drugs, such as etoposide. 
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 Jurkat T-lymphocytes in which the intrinsic pathway is inhibited due to the 
stable knockdown of Apaf-1 or overexpression of full-length XIAP, the 
BIR1/BIR2 domains of XIAP, or Bcl-2/Bcl-xL will be used to investigate the 
molecular requirements necessary for Bak-induced MOMP. 
Specific aim 2: To determine why Apaf-1 is dispensable for receptor-
mediated death in a classical “type II” Jurkat cell.  
 Apaf-1-deficient, Bcl-2/Bcl-xL-overexpressing, and BIR1/BIR2-expressing 
Jurkat cells will be used to determine the precise signaling requirements 
necessary for Fas-mediated apoptosis. 
Specific aim 3: To determine the long-term survival potential of Apaf-1-
deficient cells.   
 Apaf-1-deficient cells, which were shown previously to be resistant to 
etoposide-induced MOMP induction, will be used to investigate the longer 
term effects of etoposide incubation on mitochondrial apoptotic events 
(i.e., mitochondrial membrane potential, release of pro-apoptotic proteins 
from the mitochondria, and Bak activation). 
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Figure 11. A Comparison Between the Linear and Feed Forward 
Perspective of How the Mitochondria-Mediated Apoptosis Proceeds. 
My hypothesis favors the feed forward perspective. Caspases and 
mitochondria form an essential amplification circuit that functions as a central 
control point of genotoxic stress-induced apoptosis. Cyt c, cytochrome c; Bid, 
BH3 interacting domain; tBid, truncated Bid; Casp, caspase; IAP, inhibitor of 
apoptosis proteins; Apaf-1, apoptotic protease activating factor 1; Bak, Bcl-2 
antagonist/killer 1; Bax, Bcl-2 associated X protein; Smac, second 
mitochondrial activator caspases. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Cell Culture 
 
Wild-type Jurkat T-lymphocytes (clone E6.1) were cultured in RPMI 
1640 complete medium (Invitrogen, Carlsbad, CA) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), 2% 
(w/v) glutamine (Invitrogen), 100 U/ml penicillin (Invitrogen) and 100 μg/ml 
streptomycin (Invitrogen) at 37°C in a humidified 5% CO2 incubator.  Cells 
were maintained at their optimal growth density of 105 - 106 cells/ml.    For 
transfected Jurkat cells, 1 mg/ml Geneticin (Invitrogen) was substituted for 
penicillin and streptomycin.  All cells were re-plated in fresh complete 
nonselective medium prior to all experiments.   Cells (5 x 106) were retained 
in liquid nitrogen for long term storage in 1 ml of cryostorage medium (5% 
DMSO and RPMI 1640 with appropriate antibiotics).  Prior to submersion in 
liquid nitrogen, cells were cooled to -80°C in a Mr. Frosty (4 h – 1 week).  
Cryopreserved cells in the 5% DMSO were thawed at 37°C and diluted with 
15 ml of appropriate growth medium.  Cells were then incubated at room 
temperature (22°C) for 5 min before centrifugation  at 300 x g for 5 min.  Cell 
pellets were resuspended in 10 ml of appropriate medium and allowed to 
recover for 1 week before experiments were performed.  Apoptosis was 
induced with etoposide (10 μM) (Sigma-Aldrich) or anti-Fas antibody (100 
ng/ml) (clone CH-11, MBL International, Woburn, MA). The caspase-3/7 
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inhibitor Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-CH2F (Z-DEVD-fmk) (Kamiya 
Biomedical Company, Seattle, WA) was used at a final concentration of 25 
μM, and the Smac mimetic (compound 3) was used at a final concentration of 
100 nM. Autophagy was inhibited by treating with 3-methlyadenine (3-MA) (5 
& 20 mM: Sigma), and the 26S proteasome was inhibited with either 
bortezomib (10, 20, 40 nM) or MG132 (0.5, 1, 5 µM).     
 
3.2 Short Hairpin RNA (shRNA) Plasmid Production for Apaf-1-Deficient Cells  
  
To stably decrease the expression of Apaf-1 in wild-type Jurkat cells, a 
shRNA plasmid was created.  First, a 60-mer gene-specific targeting insert 
corresponding to nucleotides 875-893 (5’-AGGCAGATTTGCCAGAACA-3’) 
downstream of the transcription start site of the APAF-1 gene was designed.  
Two oligos (anti-sense and sense) were purchased from Integrated DNA 
Technologies (Coralville, IA).  Each oligonucleotide included the 19 base pair 
(bp) target in both sense and antisense directions separated by a 9 bp non-
complementary spacer sequence (5’-TTCAAGAGA-3’).  Oligos were 
resuspended in nuclease-free ddH2O (10 µg/μl) and annealed to produce the 
60-mer.  The annealing reaction was set up as follows: 10 µg sense oligo, 10 
µg antisense oligo and 48 µl annealing buffer (100 mM NaCl, 50 mM Hepes, 
pH 7.4).  An Eppendorf Mastercycler was used to anneal the oligos for 4 min 
at 94°C, 4 min at 85°C, 4 min at 82°C, 4 min at 80°C, 4 min at 78°C, 4 min at 
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75°C, 10 min at 70°C, 4 min at 50°C, 20 min at 37°C, 20 min at 22°C, 20 min 
at 10°C, then held at 4°C and stored at -20°C. 
Next, the pSUPER.neo vector (Oligoengine, Seattle, WA) was 
linearized for cloning of the 60-mer (annealed oligos).  The pSUPER.neo 
vector (1 μg) was incubated for 1 h at 37°C water bath with 10 U XhoI 
(Invitrogen) and 1X REact® 2 buffer (50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 
50 mM NaCl) (Invitrogen).  The vector was then incubated for 2 h at 37°C with 
10 U Bgl II (Invitrogen) and 1X REact® 3 (50 mM Tris-HCl pH 8.0, 10 
mM MgCl2, 100 mM NaCl) (Invitrogen).  Restriction enzymes were then heat 
inactivated by incubating them for 10 min at 65°C.  Linearized vector 
(pSUPER.neo) was purified on a 1% agarose gel to remove the 221 bp 
fragment and undigested plasmid away from the 4478 bp linearized fragment.  
QIAEX II agarose gel extraction kit (Qiagen, Valencia, CA) was used to 
extract DNA from agarose gel. 
Next, the 60-mer was ligated into the linearized pSUPER.neo vector.  
Linearized pSUEPER.neo vector (300 ng) was incubated with 400 - 600 ng of 
annealed oligos, 1X T4 DNA ligase buffer (250 mM Tris-HCL pH7.6, 50 mM 
MgCl2, 5 mM ATP, 5 mM Dithiothreitol (DTT), 25% (w/v) polyethylene glycol-
8000) and 1 U T4 DNA ligase (Invitrogen) for 1.5 h at 22°C, and then 4°C 
overnight.  The Bgl II site should be destroyed after ligation of the 60-mer into 
the vector.  Not all linearized vector will have the 60-mer ligated into it.  The 
linearized vector will ligate back on itself.  To optimize the chance of 
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transforming only the vectors with the 60-mer insert digest the vector again 
with 5 U Bgl II for 1 hr at 37°C.  
Subsequently, the shRNA plasmid (10 ng) was incubated with 25 μl 
TOP10 Escherichia coli cells (Invitrogen) for 45 sec at 42°C.  Heat shocked 
bacteria were then incubated on ice for 10 min before adding 250 μl of super 
optimal broth with catabolite repression (SOC; 2% trypotone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose) and incubated for 1 h at 37°C in a shaking incubator 220-250 RPM.  
Bacteria were then plated out on LB ampicillin plates (0.1 mg/ml) overnight at 
37°C.  Five to ten individual colonies were extracted and incubated with 3 ml 
of LB-ampicillin broth (0.1 mg/ml) at 37°C in a shaking incubator (220-250 
RPM) for 12 - 16 h.  Cultures were spun down at 8,000 x g for 5 min.  Pellets 
were subjected to Qiagen miniprep kit to isolate plasmid DNA.  Plasmid DNA 
was quantified using the BioMini DNA/RNA/Protein Analyzer (Shimadzu).   
Next, the plasmid was digested and run on an agarose gel to ensure 
that the plasmid contains the 60-mer insert.  Specifically, the plasmid (1 μg) 
was incubated with 10 U XhoI (Invitrogen), 10 U EcoRI, and 1X REact® 2 
buffer (50 mM Tris-HCl pH 8.0, 10 mM MgCl2, 50 mM NaCl) (Invitrogen) for 1 
h in a 37 oC water bath.  100 ng of digested plasmid and 100 ng of undigested 
plasmid DNA were run on a 1.5% agarose gel.    Vector containing the insert 
will run slightly higher (287 bp versus 249 bp) on the gel, allowing for the 
detection of which plasmid has the 60-mer insert.  One or two plasmids 
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containing the 60-mer insert was/were submitted for sequencing at University 
of Kansas Medical Center’s DNA Sequencing Core.  Once plasmid sequence 
was verified, the plasmid was transformed again into TOP10 E. coli cells and 
subjected to Qiagen Endofree Midiprep.    
          
3.3 Transfections  
 
Wild-type Jurkat T-lymphocytes (107) were washed with 1X sterile 
warm phosphate buffered saline (PBS) and pelleted by centrifugation at 300 x 
g for 5 min.  Pellets were resuspended in 800 μl RPMI and incubated with 20 
μg of plasmid DNA (pSFFV-Bcl-2, pSFFV-Bcl-xL, pSFFV-neo, pSUPER-Apaf-
1, pSUPER-neo, pcDNA3-XIAP, pcDNA3-XIAP-BIR1/BIR2, or pcDNA3-neo).  
Cells were electroporated using a Bio-Rad Gene Pulser Xcell system (0.4 cm 
cuvette, 300 V and 950 μF). Cells were then allowed to recover in RPMI 1640 
complete growth medium for 48 h at 37°C in a humidified 5% CO2 incubator.  
Selection of transfected cells was performed in the presence of 1 mg/ml 
Geneticin for several weeks (3-4 weeks).  Transfected cells were then serially 
diluted to 8 cells/ml and 125 μl/well were plated out in a 96-well plate.  Wells 
were observed every few days to ensure the presence of only 1 cell was 
initially added to each well.  Single-cell clones of Bcl-2- or Bcl-xL-
overexpressing cells, Apaf-1-silenced cells, and cells overexpressing full-
length XIAP or the BIR1/BIR2 domains of XIAP were produced.  The extent of 
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protein overexpression or knockdown was determined by Western blot 
analysis. 
 
3.4 Flow Cytometry Measurements for Cell Death, Mitochondrial Membrane 
Potential (ΔΨ), and Bak Activation 
 
Phosphatidylserine (PS) exposure on the outer leaflet of the plasma 
membrane was detected by staining with Annexin V-FITC (BD PharMingen) 
and disruption in the plasma membrane was detected by staining DNA with 
the non-cell permeable dye propidium iodide (PI).  In brief, 106 cells were 
pelleted by centrifuging at 300 x g for 5 min, following etoposide or anti-Fas 
treatment and washed with cold PBS.  Cells were washed with PBS and 
centrifuged at 300 x g for 5 min.  Pellets were resuspended in 500 μl of 
binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) 
containing 1.5 μg annexin V-FITC and 5 μl PI.  Cells were then analyzed by 
flow cytometry with the BD LSRII and BD FACS Diva v6.1.2 software.  
For ΔΨ determination, cells were stained with DiIC1(5) (Invitrogen), 
which is a cell-permeable dye that accumulates in mitochondria with active 
membrane potentials to produce bright far-red fluorescence.  Specifically, the 
fluorrochrome emits a red light at 658 nM when excited with a 633 nM laser.  
The intensity of the fluorescence decreases as ΔΨ diminishes.  Briefly, cells 
(106) were pelleted by centrifugation at 300 x g for 5 min at the end of the 
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experiment.  Cells were then washed once in PBS, and resuspended in 1 ml 
of warm PBS.  Next, 5 μl of DiIC1(5) (10 μM) were added to the cells and 
incubated in a humidified 5% CO2 incubator at 37°C for 15 min.  Cells were 
pelleted by centrifugation at 300 x g for 5 min and resuspended in 500 μl of 
cold PBS.  Cells were then analyzed by flow cytometry with BD LSRII and BD 
FACS Diva v6.1.2 software. 
For detection of activated Bak by flow cytometry, cells (106) were 
washed in PBS, fixed in 400 μl of 0.25% paraformaldehyde for 5 min, 
subsequently washed two times with 1% fetal bovine serum in PBS, and 
incubated in 50 μl of staining buffer (1% fetal bovine serum and 100 μg/ml 
digitonin in PBS) with a conformation-specific mouse monoclonal antibody 
against Bak (1:30; AM03, Calbiochem) for 30 min at room temperature (22°C). 
Then, cells were washed and resuspended in 50 μl of staining buffer 
containing 0.25 μg of Alexa Fluor 488-labeled chicken anti-mouse antibody 
for 30 min in the dark. Cells were washed again and analyzed by flow 
cytometry.  Analysis and histogram overlays were performed using FlowJo 
software (Tree Star, Ashland, OR). 
 
3.5 Western Blotting 
 
Cells (5 x 106) were centrifuged at 300 x g for 5 min.  Pelleted cells 
were then resuspended and lysed in 200 μl of ice-cold lysis buffer (10 mM 
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Tris/HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 0.1% Nonidet P-
40) supplemented with a mixture of protease inhibitors (Complete Mini EDTA-
Free, Roche Applied Science).  Resuspended pellets were incubated on ice 
for 10 min before protein concentrations were determined using the 
bicinchoninic acid assay (Pierce).  BSA standards (0 μg, 1 μg, 2 μg, 4 μg, 8 
μg, 16 μg, 32 μg, 64 μg) were used to determine sample protein 
concentrations.  Then protein was mixed with loading 1X sample buffer (50 
mM Tris HCl pH 6.8, 2% SDS, 6% glycerol, 1% β-mercaptoethanol, 0.004 % 
bromophenol blue) before being incubated for 5 min at 100°C.   Protein (30 – 
40 μg) was loaded on a polyacrylamide gel (8 - 15%).  When blotting for Apaf-
1 an 8% polyacrylamide gel was used, and when blotting for caspases a 15% 
gel was used.  Polyacrylamide gels were run for ~ 40 min at 200 volts in a 
Mini-PROTEAN® 3 Cell (BioRad, Hercules, CA) in electrode buffer (25 mM 
Tris, 192 mM glycine, 1% SDS).  Next, proteins were transferred to 
nitrocellulose membrane in a BioRad transfer apparatus for 1 h 15 min at 
100 volts using the Trans-Blot® Electrophoretic Transfer Cell (BioRad) with 
SDS-PAGE Gel buffer (25 mM Tris, 192 mM glycine, 20% v/v methanol, pH 
8.3).   Nitrocellulose membranes were incubated in 5% non-fat dry milk/PBS 
for 1 h at 22°C with gentle shaking.  Nitrocellulose membranes were rinsed in 
PBS before being incubated with primary antibody overnight.   
The primary antibodies were diluted in 1% BSA in PBS.  Nitrocellulose 
membranes were incubated with primary antibody overnight at 4°C with 
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gentle shaking.  Antibodies and dilutions used were mouse 1:500 anti-Apaf-1 
(clone 94408, R&D Systems, Minneapolis, MN), 1:1,000 rabbit anti-Bax (Cell 
Signaling Technology, Danvers, MA), 1:1,000 rabbit anti-Bak NT (Millipore), 
1:500 mouse anti-Bcl-2 (DakoCytomation, Glostrup, Denmark), 1:1,000 rabbit 
anti-Bcl-xL (clone 54H6, Cell Signaling), 1:5,000 mouse anti-β-actin (clone 
AC-15, Sigma), 1:1,000 rabbit anti-Bid (Cell Signaling), 1:1,000  rabbit anti-
caspase-3 (clone 8G10, Cell Signaling), 1:1,000  rabbit anti-caspase-6 (Cell 
Signaling), 1:1,000 rabbit anti-caspase-7 (Cell Signaling), 1:1,000 mouse anti-
caspase-8 (clone 1C12, Cell Signaling), 1:1,000 rabbit anti-caspase-9 (Cell 
Signaling), 1:1,000 mouse anti-cytochrome c (clone 7H8.2C12, Pharmingen), 
1:5,000 rabbit anti-glyceraldehyde-3-phosphate dehydrogenase (Trevigen, 
Gaithersburg, MD), 1:500 mouse anti-Myc (clone 9E10, Santa Cruz 
Biotechnology), 1:1,000 mouse anti-Smac/DIABLO (Cell Signaling), and 
1:1,000  mouse anti-XIAP (clone 28, BD Transduction Laboratories). 
Nitrocellulose membrane was washed with 1X PBS for 10 min, 1X 
PBST for 10 min, and 1X PBS for 10 min all at room temperature (22°C) with 
gentle shaking to remove excess primary antibody.  Membranes were then 
incubated with horseradish peroxidase-conjugated secondary antibody for 1 h 
at room temperature (22°C) with gentle shaking.  Secondary antibodies were 
diluted to 1:10,000 in 2.5% non-fat dry milk in PBS.  Secondary antibodies 
used included goat anti-mouse IgG, (H+L) and goat anti-rabbit IgG (Thermo 
Scientific, Pierce Biotechnology).  Next, nitrocellulose membranes were 
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washed with 1X PBS for 10 min, 1X PBST for 10 min and 1X PBS for 10 min 
all at room temperature (22°C) with gentle shaking.  Afterward, the 
nitrocellulose membrane was patted dry and incubated with 3 ml of 50:50 
ECL Detection Reagent 1:ECL Detection Reagent 2 (Amersham, 
Buckinghamshire, UK) for 1-2 min before developing using classic 
autoradiography film BX (MidSci, St. Louis, Missouri).           
 
3.6 Subcellular Fractionation  
 
Subcellular fractionation was used to determine whether mitochondria 
released pro-apoptotic factors (cytochrome c and Smac) into the cytosol.  
Cells (106) were centrifuged at 300 x g for 5 min at room temperature (22°C) 
and washed in cold PBS.  Cells were then centrifuged again at 300 x g for 5 
min at room temperature (22°C).  Cells were resuspended in 50 μl of buffer 
(140 mM mannitol, 46 mM sucrose, 50 mM KCl, 1 mM KH2PO4, 5 mM MgCl2, 
1 mM EGTA, 5 mM Tris, pH 7.4) supplemented with a mixture of protease 
inhibitors (Complete Mini-EDTA Free), and permeabilized with 3 μg of 
digitonin (Sigma) on ice for 10 min.  Plasma membrane permeabilization was 
monitored by trypan blue staining.  Cell suspensions were centrifuged at 
12,000 x g for 10 min at 4°C to separate the cytosol (supernatant) from the 
mitochondria (pellet). Supernatant and pellet fractions were subjected to 
Western blot analysis.   
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3.7 Determination of Bak Oligomerization  
 
Bak oligomerization can be visualized by Western Blot analysis after 
incubating with a cross-linking agent (Wei et al., 2000).  For detection of Bak 
oligomerization, cells (2.5 x 106) were harvested after treatment with drug by 
centrifugation at 300 x g for 5 min at room temperature (22°C).  Cells were 
then washed in cold PBS and centrifuged for 5 min at 300 x g at room 
temperature (22°C).  Cells were then resuspended in 200 μl of 100 mM 
EDTA/PBS and incubated with the cross-linking agent bismaleimidohexane 
(BMH) (1 mM).  After the addition of BMH, tubes were mixed by inverting 2-
3X before incubation for 30 min at room temperature (22°C) while rocking.  
The reaction was quenched with 100 mM DTT for 15 min at room 
temperature (22°C) while rocking.  The cell suspension was then centrifuged 
at 500 x g for 5 min and processed for Western blot analysis.  Protein 
concentration of cell lysate is unable to be determined due to the BMH, 
therefore approximately 2 X 106 cells were loaded onto a 12% polyacrylamide 
gel.   
  
3.8 Scanning Electron Microscopy 
 
Cells (106) were washed in PBS and pelleted.  Pellet was fixed in 
fixative (2% gluteraldehyde in 0.1 M sodium cacodylate, pH 7.4) for 20 min.  
Cells were washed twice (0.1 M sodium cacodylate, pH 7.4) before being 
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post-fixed for 1 h (1% osium tetroxide buffer in 0.1 M sodium cacodylate, pH 
7.4).  Cells were washed three times with dH2O and dehydrated in a series of 
ethanol washes as follows: 30%, 70%, 80%, 95%, 100%, 100% for 10 min 
each.  Next, cells were incubated in propylene oxide for 10 min.  Cell pellets 
were then infiltrated overnight in 1:1 ratio of propylene oxide:embed 812 resin 
medium mixture (Electron Microscopy Sciences, Inc).  Cell pellets were then 
incubated for 1 h in Embed 812 resin mixture. Subsequently, cells were 
placed in flat embedding molds with fresh resin and cured overnight in 60oC 
oven.  Sections were cut (80 nm) using a Diatome diamond knife on a Leica 
UCT ultramicrotome. Sections were then stained with 1% uranyl acetate and 
Sato’s modified lead citrate.  Lastly, sections were viewed and photographed 
using a J.E.O.L. 100CXII Transition Electron Microscopy at 80 KV.       
 
 55
CHAPTER 4: CASPASE-MEDIATED BAK ACTIVATION AND 
CYTOCHROME C RELEASE DURING INTRINSIC APOPTOTIC CELL 
DEATH IN JURKAT CELLS 
(J. Biol. Chem. 283: 35532-35538) 
 
4.1 Abstract 
   
MOMP and the release of intermembrane space proteins, such as 
cytochrome c, are early events during intrinsic (mitochondria-mediated) 
apoptotic signaling. Although this process is generally accepted to require the 
activation of Bak or Bax, the underlying mechanism responsible for their 
activation during true intrinsic apoptosis is not well understood. In the current 
study, we investigated the molecular requirements necessary for Bak 
activation using distinct clones of Bax-deficient Jurkat T-lymphocytes in which 
the intrinsic pathway had been inhibited. Cells stably overexpressing Bcl-
2/Bcl-xL or stably depleted of Apaf-1 were equally resistant to apoptosis 
induced by the DNA-damaging anticancer drug etoposide as determined by 
phosphatidylserine externalization and caspase activation. Strikingly, 
characterization of mitochondrial apoptotic events in all three drug-resistant 
cell lines revealed that, without exception, resistance to apoptosis was 
associated with an absence of Bak activation, cytochrome c release, and 
mitochondrial membrane depolarization. Furthermore, we found that 
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etoposide-induced apoptosis and mitochondrial events were inhibited in cells 
stably overexpressing either full-length XIAP or the BIR1/BIR2 domains of 
XIAP. Combined, our findings suggest that caspase-mediated positive 
amplification of initial mitochondrial changes can determine the threshold for 




Apoptosis is a gene-regulated form of cell death that is critical for 
normal development and tissue homeostasis. Disruptions in the control of 
apoptosis can contribute to the onset of various pathological states including 
cancer, where avoidance of apoptosis confers a survival advantage to 
tumorigenic cells. Apoptosis is mediated by a family of cysteine proteases 
that cleave after aspartate residues (caspases) and can be activated by two 
distinct signaling pathways.   
The intrinsic (mitochondria-mediated) pathway is activated by cytotoxic 
stressors, such as DNA damage, γ-radiation, growth factor withdrawal, and 
heat. Such stimuli are known to cause MOMP and stimulate the release of 
cytochrome c, Smac, (also known as DIABLO), and Omi (also known as 
HtrA2) into the cytosol, where they work together to activate the initiator pro-
caspase-9 within the apoptotic protease-activating factor-1 (Apaf-1) 
apoptosome complex (Li et al., 1997) .  Once activated, caspase-9 activates 
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effector pro-caspase-3 or -7, which, in turn, can cleave various protein 
substrates, leading to the morphological and biochemical features of 
apoptosis. 
The process of MOMP is generally thought to require the activation of 
a multidomain Bcl-2 family protein, notably Bax or Bak (Chipuk and Green, 
2006; Ow et al., 2008).  Cells deficient in either Bax or Bak display relatively 
minor defects in apoptosis, whereas doubly deficient cells are often found to 
be highly resistant to mitochondria-mediated apoptosis induced by a variety of 
stimuli (Lindsten et al., 2000; Wei et al., 2001).  Normally, these proteins exist 
as inactive monomers either in the cytosol (Bax) or associated with the 
mitochondria (Bak). Activation of Bax and Bak coincides with their homo-
oligomerization, which is thought to occur by one of two mechanisms. One 
model argues for the existence of “sensitizer” Bcl-2 homology 3 (BH3)-only 
proteins, such as Noxa and Bad, that can displace “activator” BH3-only Bcl-2 
family proteins, such as Bim, truncated Bid (tBid), and Puma, from a 
prosurvival protein, such as Bcl-2 or Bcl-xL, to activate Bak or Bax (Kim et al., 
2006a).  The second model indicates that BH3-only proteins bind and 
neutralize prosurvival Bcl-2 proteins that normally keep Bak or Bax inactive 
(Chen et al., 2005; Willis et al., 2007) .  A well characterized example of Bak 
or Bax activation being induced by a BH3-only protein is during receptor-
mediated apoptosis in so-called type II cells. In this case, death receptor 
ligation activates caspase-8, which, in turn, cleaves the cytosolic BH3-only 
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protein Bid to tBid (Li et al., 1998; Luo et al., 1998), resulting in the direct or 
indirect activation of Bak or Bax. A similar emergent understanding of a 
mechanism responsible for the activation of Bak/Bax during true 
mitochondria-mediated apoptosis is currently lacking. 
In this regard, the aim of the current study was to investigate the 
signaling requirements for MOMP during intrinsic apoptosis, as well as to help 
define the elusive threshold a cell must cross in order to be irreversibly 
committed to undergo this form of cell death. We have engineered several 
clones of Bax-deficient Jurkat cells in which the intrinsic pathway is inhibited 
due to the stable overexpression of Bcl-2 or Bcl-xL, the stable knockdown of 
Apaf-1, or the overexpression of full-length XIAP or the baculoviral inhibitor of 
apoptosis protein repeat 1 and 2 (BIR1/BIR2) domains of XIAP. The results 
indicated that all five of the gene-manipulated Jurkat cell lines were similarly 
resistant to etoposide-induced apoptosis. As anticipated, Bcl-2/Bcl-xL-
overexpressing cells were refractory to all etoposide induced mitochondrial 
events. Strikingly, however, Apaf-1-silenced cells and cells overexpressing 
full-length XIAP or the BIR1/BIR2 domains of XIAP were also found to be 
impaired in their ability to activate Bak, release cytochrome c, or lose 




4.3 Results and Discussion 
 
4.3.1 Blockade of the Intrinsic Pathway by Depleting Apaf-1 or 
Overexpressing Bcl-2/Bcl-xL Completely Inhibits Etoposide-Induced Apoptosis 
in Jurkat Cells 
 
The largest body of evidence indicates that MOMP and the release of 
intermembrane space proteins, such as cytochrome c, involves the activation 
of multidomain pro-apoptotic Bcl-2 family proteins Bak and Bax (Chipuk et al., 
2006; Ow et al., 2008).  Although it is clear that active caspase-8 within the 
extrinsic apoptotic pathway can activate Bak or Bax by cleaving the BH3- only 
protein Bid to tBid (Garrido et al., 2006; Li et al., 1998; Luo et al., 1998), a 
similar prominent role for one or more caspases in modulating MOMP during 
true intrinsic apoptosis is not appreciated. In some instances, incubation of 
cells with the topoisomerase II inhibitor etoposide was found to induce 
caspase-8-mediated cleavage of Bid by stimulating an up-regulation of Fas 
ligand that, in turn, activated the Fas receptor (Friesen et al., 1996; Kasibhatla 
et al., 1998; Petak et al., 2000) .  However, other studies, including our own 
unpublished results, have shown that caspase-8-deficient cells are sensitive 
to etoposide-induced apoptosis (Juo et al., 1998).  Other evidence has 
suggested that caspase-2 may be able to activate Bax by first cleaving Bid in 
response to stress (Bonzon et al., 2006; Gogvadze et al., 2006; Guo et al., 
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2002; Upton et al., 2008), although it was also shown that Bid is a relatively 
poor substrate for caspase-2 (Bonzon et al., 2006; Guo et al., 2002).  In 
addition, we recently demonstrated that Apaf-1 is required for etoposide-
induced activation of all caspases, suggesting that most, if not all, caspase 
activation occurs downstream of apoptosome formation (Franklin and 
Robertson, 2007). 
To investigate the molecular requirements for etoposide-induced 
MOMP, we initially used the same Apaf-1-deficient Jurkat cells described 
previously (Figure 12A, lane 5) (Franklin and Robertson, 2007), as well as 
cells in which the intrinsic pathway had been inhibited due to the 
overexpression of either Bcl-xL or Bcl-2 (lanes 2 and 3). As illustrated in 
Figure 12A, manipulating the level of expression of Apaf-1, Bcl-2, or Bcl-xL did 
not result in any alteration in the expression of the other two proteins. 
According to Figure 12B, control-transfected Jurkat cells were induced to 
undergo apoptosis (~30%), as determined by annexin V-FITC labeling of 
externalized phosphatidylserine on the plasma membrane, when incubated in 
the presence of a clinically relevant concentration of etoposide (10 μM) for 6 h. 
By comparison, Jurkat cells in which either Apaf-1 expression had been 
silenced or an anti-apoptotic Bcl-2 family protein had been overexpressed 
were totally protected from etoposide-induced apoptosis (Figure 12B). In 
agreement with these findings, Western blot analysis of cell lysates obtained 
at 6 h post-etoposide treatment revealed that proteolytic processing of pro-  
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Figure 12. Inhibiting the Intrinsic Pathway by Bcl-2/Bcl-xL 
Overexpression or Apaf-1 Knockdown Blocks Etoposide-Induced 
Apoptosis in Jurkat Cells. 
A, wild-type, control-transfected, Bcl-xL- and Bcl-2-overexpressing, and Apaf-
1-deficient Jurkat clones were harvested and lysed for Western blotting. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
loading control. B, cells (106 /ml) were cultured with DMSO or 10 μM 
etoposide for 6 h and processed for cell death determination by flow 
cytometric analysis of annexin V-FITC and propidium iodide staining. 
Quadrants are defined as live (lower left), early apoptotic (lower right), late 
apoptotic (upper right), and necrotic (upper left). Numbers refer to the 
percentage of cells in each quadrant. C, duplicate aliquots of cells in B, were 
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caspase-8, -9, and -3 occurred in wild-type and control-transfected cells, but 
not in any of the three gene-manipulated clones (Figure 12C). In addition, 
cleavage of Bid to tBid was observed only in etoposide-treated wild type and 
vector control cells, suggesting that Bid cleavage occurs downstream of the 
apoptosome.  Taken together, these data clearly demonstrate that silencing 
Apaf-1 or overexpressing Bcl-2/Bcl-xL results in a total blockade of the 
intrinsic pathway in Jurkat cells. 
  
4.3.2 Bak Activation Is Impaired in Apaf-1-Deficient Cells Treated with 
Etoposide 
 
In many settings, cytochrome c release is a rapid, complete, and 
irreversible event that represents the “point of no return” within the intrinsic 
apoptotic pathway (Goldstein et al., 2000).  In addition, it is generally 
accepted that caspase-9 activation requires cytochrome c-mediated 
oligomerization of Apaf-1 and that cytochrome c release occurs independently 
of downstream caspase activity (Bossy-Wetzel et al., 1998; Li et al., 1997; 
Susin et al., 1999). In this regard, cells deficient in Apaf-1, caspase-9, or 
executioner caspases-3 and -7 would be expected to undergo MOMP and 
release intermembrane space proteins with the same kinetics as wild-type 
cells. However, some evidence is at odds with such a view of the intrinsic 
pathway.  For instance, it has been shown that pro-caspases can be activated 
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by a cytochrome c- and apoptosome-independent, but Apaf-1-dependent, 
mechanism in thymocytes exposed to γ-radiation (Hao et al., 2005).  Also, 
Lakhani et al. (2006) demonstrated that caspase-3 and -7 are key mediators 
of Bax-directed mitochondrial apoptotic events in response to ultraviolet 
radiation. 
Having demonstrated that Jurkat cells in which either an anti-apoptotic 
Bcl-2 family protein had been overexpressed or Apaf-1 had been knocked 
down, were equally impaired in their ability to activate caspases, we next 
evaluated the different cells for changes in ΔΨ. As illustrated in Figure 13A, a 
partial loss of ΔΨ in response to 10 μM etoposide was detected in control-
transfected Jurkat cells, which activated caspases (Figure 12C), whereas 
Apaf-1-deficient and Bcl-2/Bcl-xL-overexpressing cells did not lose ΔΨ. These 
data are consistent with evidence indicating that the loss of ΔΨ during 
apoptotic cell death requires caspase mediated proteolytic inactivation of the 
respiratory complex I subunit NDUSF1 (Ricci et al., 2004).  Because a drop in 
ΔΨ is often associated with the release of mitochondrial intermembrane 
space proteins into the cytosol, we next investigated whether the release of 
cytochrome c and Smac had occurred in the different cell types. Consistent 
with the membrane potential results, etoposide treatment stimulated a strong 
release of cytochrome c and Smac only in vector control cells (Figure 13B, 
lane 6 versus 5). By comparison, cells overexpressing either Bcl-2 or Bcl-xL 
failed to release cytochrome c or Smac in response to etoposide (Figure 13B,  
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Figure 13. Apaf-1 is Essential for MOMP Induction and Bak Activation in 
Response to Etoposide. 
A, control transfected, Bcl-xL- and Bcl-2 overexpressing, and Apaf-1-deficient 
Jurkat clones (106/ml) were cultured in the presence or absence of DMSO or 
10 μM etoposide for 6 h, harvested, and processed for mitochondrial 
membrane potential (ΔΨ) determination by flow cytometry. Reduced DiIC1(5) 
fluorescence is indicative of a loss of ΔΨ, and numbers refer to the 
percentage of cells that underwent a dissipation of ΔΨ. B, duplicate aliquots 
of cells in A were harvested and processed for subcellular fractionation. 
Supernatant (s) and pellet (p) fractions were analyzed by Western blotting. C, 
whole-cell lysates of Jurkat (E6.1) and MCF-7 (positive control for Bax 
expression) cells were separated by SDS-PAGE and Western-blotted. D and 
E, wildtype, control-transfected, Bcl-xL- and Bcl-2-overexpressing, and Apaf-
1-deficient Jurkat clones (106/ml) were cultured in the absence or presence of 
DMSO or 10 μM etoposide for 6 h and processed for determination of Bak 
oligomerization by Western blotting (D) or Bak activation by flow cytometric 
analysis (E). Numbers in E refer to the percentage increase in Bak-associated 
fluorescence between etoposide- and DMSO-treated samples. MOMP, 
mitochondrial outer membrane permeablization; shRNA, short hairpin RNA; 
















































































































lanes 1–4), and Apaf-1-deficient cells released only a trace of each protein 
(lane 8 versus 7). 
 Numerous studies from other laboratories have shown that the 
induction of MOMP is tightly controlled by pro- and anti-apoptotic members of 
the Bcl-2 family of proteins (Chipuk and Green, 2006; Scorrano and 
Korsmeyer, 2003).  In fact, it is often the ratio of pro- to anti-apoptotic proteins 
that determines the sensitivity of a cell to a given intrinsic apoptotic stimulus. 
Induction of MOMP by either of the multidomain pro-apoptotic proteins Bax 
and Bak is thought to require the prior activation of a BH3-only Bcl-2 family 
protein (Letai, 2008).  The anti-apoptotic proteins Bcl-2 and Bcl-xL prevent 
MOMP by directly binding Bax/Bak or by preventing their activation by 
inhibiting BH3-only proteins (Youle and Strasser, 2008).  As mentioned earlier, 
Bax is largely cytosolic in healthy cells, whereas Bak resides on the outer 
mitochondrial membrane. Both proteins are monomeric in their inactive state, 
and activation coincides with their homo-oligomerization to form protein- 
permeable pores in the outer mitochondrial membrane. 
 To investigate the extent to which differences in the release of 
cytochrome c and Smac corresponded to differences in the activation of Bax 
or Bak, we first evaluated the different cell clones for the expression of Bax 
and Bak. Interestingly, Western blot results revealed that Jurkat (E6.1) cells 
express Bak, but not Bax, protein (Figure 13C, lane 1). Thus, to evaluate 
changes in Bak under the different conditions, we first investigated whether 
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Bak underwent oligomerization using the crosslinking agent BMH. As 
illustrated in Figure 13D, cross-linked Bak complexes consistent with dimers 
were observed in wild-type (lane 2) and control-transfected (lane 8) Jurkat 
cells treated with 10 μM etoposide for 6 h. These findings were in agreement 
with results obtained using an active conformation-specific monoclonal Bak 
antibody and flow cytometric analysis, where Bak activation amounts to a shift 
to the right in the resulting histogram (Figure 13E). Consistent with previous 
reports, etoposide-induced oligomerization (Figure 12D) and activation 
(Figure 13E) of Bak were blocked in cells overexpressing Bcl-2 or Bcl-xL, 
perhaps because of their reported ability to sequester activator BH3-only 
proteins (Kim et al., 2006a) or to bind Bak directly (Chen et al., 2005; Willis et 
al., 2007).  Significantly, Bak oligomerization and activation were also strongly 
inhibited in Apaf-1-deficient Jurkat cells (Figure 13D, lane 10 versus 9, and 
13E), which likely accounts for the lack of cytochrome c and Smac release in 
these cells following etoposide treatment (Figure 13B, lane 8 versus 7). 
Combined, these data raise the distinct possibility that signaling events, which 
are widely believed to be post-mitochondrial, are essential for Bak-mediated 






4.3.3 Overexpression of Full-Length XIAP or the BIR1/BIR2 Domains of XIAP 
Inhibits Etoposide-Induced Apoptosis 
 
Because Bak activation and MOMP were strongly inhibited in Apaf-1-
deficient cells, we were next interested to determine whether this was due to 
a direct role of Apaf-1 in mediating MOMP or whether the absence of Bak 
activation and the release of intermembrane space proteins were attributable 
to the lack of etoposide-induced caspase activation. Because of the reported 
problems with the selectivity of “specific” peptide based caspase inhibitors 
(Berger et al., 2006; McStay et al., 2008), we developed a genetic strategy to 
inhibit caspases residing downstream of apoptosome formation.  The 
approach was to modulate the expression of XIAP. 
 XIAP is a member of the inhibitor of apoptosis protein family that 
potently inhibits apoptotic cell death by specifically targeting caspase-9, -3, 
and/or -7 (Deveraux et al., 1997).  Recent work has described the regions of 
XIAP that are responsible for its caspase inhibitory properties (Scott et al., 
2005; Shiozaki et al., 2003).  Specifically, a region of XIAP that includes the 
BIR2 domain inhibits caspase-3 and -7, whereas the BIR3 domain inhibits 
caspase-9. In a cell dying by apoptosis, the anti-apoptotic activity of XIAP can 
be inhibited by two mitochondrial intermembrane space proteins, namely 
Smac (Du et al., 2000; Verhagen et al., 2000) and Omi (Hegde et al., 2002; 
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Suzuki et al., 2001; Verhagen et al., 2002) that are released into the cytosol, 
along with cytochrome c, following the induction of MOMP. 
 For our studies, we generated Jurkat cells that overexpressed either 
full-length XIAP (Figure 14A, left panel) or the BIR1/BIR2 domains of XIAP 
(right panel). We hypothesized that, if full-length XIAP inhibited Bak activation 
and MOMP, then cells expressing only the BIR1/BIR2 domains would shed 
light on whether this was largely a caspase-9- or caspase-3/7-mediated effect. 
The primary justification for expressing BIR1/BIR2, instead of BIR2 alone, is 
that XIAP-BIR1/BIR2 has been shown to express better in mammalian cells 
than XIAP-BIR2 alone (Scott et al., 2005). As illustrated in Figure 14B, vector 
control cells underwent apoptosis (~48%) when incubated in the presence of 
10 μM etoposide for 6 h. By comparison, cells overexpressing full-length XIAP 
or the BIR1/BIR2 domains underwent ~8 and ~13% apoptosis, respectively. 
Western blot analysis of cell lysates generated after 6 h of etoposide 
incubation revealed that extensive cleavage of caspase-9, -3, and -7 had 
occurred, as well as the partial disappearance of the precursor form of 
caspase-6, only in control-transfected cells (Figure 14C).  Overall, these 
findings demonstrate that cells overexpressing either XIAP or the BIR1/BIR2 
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Figure 14. Overexpression of XIAP or Myc-BIR1/BIR2 Inhibits Etoposide-
Induced Apoptosis. 
A, control transfected, XIAP-overexpressing, and Myc-BIR1/BIR2-
overexpressing Jurkat clones were harvested and lysed for Western blotting.-
Actin was used as a loading control. B, cells (106/ml) were cultured with 
DMSO or 10 μM etoposide for 6 h and processed for cell death determination 
by flow cytometric analysis of annexin V-FITC and propidium iodide staining. 
Quadrants are defined as live (lower left), early apoptotic (lower right), late 
apoptotic (upper right), and necrotic (upper left). Numbers refer to the 
percentage of cells in each quadrant. C, duplicate aliquots of cells in B were 
harvested and lysed for Western blotting. Casp, caspase.
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4.3.4 Activation of Bak and Induction of MOMP are Dependent on 
Downstream Caspase Activation 
 
 Once we had demonstrated that cells expressing either of the two 
XIAP constructs were similarly resistant to etoposide-induced apoptosis, the 
next step was to determine the extent to which this involved an inhibition of 
mitochondrial apoptotic events. As illustrated in Figure 15A, slightly more than 
half of the etoposide-treated vector control cells experienced a loss of ΔΨ, 
whereas XIAP- and BIR1/BIR2-overexpressing cells underwent a more 
modest drop in ΔΨ of ~10 and 11%, respectively. In agreement with the ΔΨ 
findings, vector control cells were triggered to undergo etoposide-induced 
MOMP as assessed by Western blot analysis of cytochrome c and Smac 
release into the cytosol (Figure 15B, lane 2 versus 1). By comparison, XIAP 
overexpressors, and to a slightly lesser extent BIR1/BIR2-expressing cells, 
were refractory to etoposide-induced cytochrome c and Smac release (Figure 
15B, lanes 3–6). Finally, we were interested to know whether the inhibition of 
cytochrome c and Smac release in the XIAP- and BIR1/BIR2-overexpressing 
cells coincided with a similar inhibition of Bak activation in cells incubated with 
etoposide. As shown in Figure 15C, the results indicated that incubation of 
vector control cells with 10 μM etoposide for 6 h induced large-scale Bak 
oligomerization (lane 2). By comparison, etoposide-treated XIAP-
overexpressing cells failed to activate Bak (Figure 15C, lane 4), and only a  
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Figure 15. Downstream Caspases Play an Integral Role in Bak Activation 
and MOMP Induction. 
A, control-transfected, XIAP-overexpressing, and Myc-BIR1/BIR2-expressing 
Jurkat clones (106/ml) were cultured in the presence or absence of DMSO or 
10 μM etoposide for 6 h, harvested, and processed for determination by flow 
cytometry. Reduced DiIC1(5) fluorescence is indicative of a loss of, and 
numbers refer to the percentage of cells that underwent a dissipation of ΔΨ. 
B, duplicate aliquots of cells in A were harvested and processed for 
subcellular fractionation. Supernatant (s) and pellet (p) fractions were 
analyzed by Western blotting. C, cells were cultured as described in A and 
processed for determination of Bak oligomerization by Western blotting. ΔΨ, 
mitochondrial membrane potential; BMH, bismaleimidohexane; Cyt c, 
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trace amount of active Bak was detected in BIR1/BIR2-expressing cells (lane 
6). Taken together, these findings strongly suggest that downstream 
caspases play an essential role in the activation of Bak and in the induction of 
MOMP during etoposide-induced apoptosis. They also imply that the reason 
etoposide-induced mitochondrial apoptotic events were inhibited in Apaf-1-
deficient cells is due to the fact that caspases were not activated, rather than 
any direct role for Apaf-1 in mediating Bak activation or MOMP. 
 
4.4 Concluding Remarks 
 
Ever since Wang and colleagues (Liu et al., 1996) made the seminal 
observation that the induction of the apoptotic program in cell-free extracts 
requires cytochrome c (and dATP), a major effort has been made to 
characterize the molecular mechanisms responsible for the regulation of the 
intrinsic (mitochondria-mediated) apoptotic pathway. A more complete 
understanding of how this pathway is regulated has ensued, and it is now 
widely accepted that various cytotoxic stressors kill cells by activating the 
intrinsic pathway. 
As mentioned previously, one of the earliest events during true intrinsic 
apoptosis is the activation of Bax and/or Bak (Wei et al., 2001).  Under 
unstressed conditions, Bax and Bak can be found in the cytosol and on the 
outer mitochondrial membrane, respectively, as monomers (Youle and 
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Strasser, 2008).  Activation of Bax and Bak is marked by their homo-
oligomerization to form pores in the outer mitochondrial membrane through 
which intermembrane space proteins, including cytochrome c, can be 
released into the cytosol to promote apoptosome-dependent activation of 
caspases. Although caspase-8-mediated cleavage of Bid to tBid is known to 
play an important role in the activation of Bak or Bax during receptor-
mediated apoptosis in type II cells, the underlying mechanism responsible for 
the activation of these multidomain pro-apoptotic proteins within the intrinsic 
apoptotic pathway is not well understood. In cells with normal p53, genotoxic 
anticancer drugs have been suggested to activate Bax/Bak because of a 
transcriptional up-regulation of Puma (Jeffers et al., 2003; Villunger et al., 
2003) .  However, because cancer cells, including Jurkat (E6.1), are often 
defective in their p53 signaling pathway, a general non-redundant role for 
Puma up-regulation seems unlikely. In fact, most evidence in the literature 
indicates that stress-induced activation of Bak and Bax requires the presence 
of either Bid or Bim, irrespective of p53 status (Letai, 2008).  However, insight 
into the precise mechanism(s) responsible for the activation of these two 
BH3-only proteins in response to genotoxic injury is currently lacking. 
A common view of the mitochondrial apoptotic pathway is that 
cytochrome c release is an all-or-none phenomenon in that, once a single 
mitochondrion in an “apoptosing” cell has released its cytochrome c, all 
mitochondria in that cell will release all of their cytochrome c within about 10 
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min (Chipuk et al., 2006; Goldstein et al., 2005; Goldstein et al., 2000; 
Waterhouse et al., 2001).  Two additional viewpoints are (i) pro-caspase-9 
activation occurs in a cytochrome c-dependent manner involving the 
formation of an Apaf-1 apoptosome complex, and (ii) the release of 
cytochrome c and other intermembrane space proteins from mitochondria 
occurs by a mechanism that is independent of downstream caspases (Bossy-
Wetzel et al., 1998; Hao et al., 2005; Li et al., 1997; Sun et al., 1999b; 
Waterhouse et al., 2001; Wilkinson et al., 2004).  However, our observations, 
as well as other lines of evidence, do not support a strictly linear view of the 
mitochondrial apoptotic pathway. As mentioned previously, a cytochrome c- 
and apoptosome-independent, but Apaf-1-dependent, mechanism leading to 
caspase activation has been described (Hao et al., 2005).  Also, there is 
evidence that caspase-3 and -7 can be key mediators of Bax-directed 
mitochondrial apoptotic events in response to UV radiation (Lakhani et al., 
2006).  Furthermore, our results demonstrate that downstream caspases are 
required for Bak activation and MOMP induction in response to the genotoxic 
drug etoposide in Jurkat cells.  
In summary, our findings support a model of the intrinsic pathway in 
which caspase-mediated positive amplification of initial mitochondrial events 
can function as an essential part of cell death and, as such, may determine 
whether a given cell dies in response to stress. Furthermore, it is tempting to 
speculate that at least one reason a single biologically active apoptosome 
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complex is around 1 MDa in size (Cain et al., 2000; Zou et al., 1999) and 
consists of seven Apaf-1 and cytochrome c molecules coassembling to form a 
wheel-like complex with seven spokes (Acehan et al., 2002) is to prevent the 
unintentional activation of caspase-9. In other words, it seems plausible that, 
in instances in which a weak apoptotic signal induces the release of miniscule 
amounts of cytochrome c or if mitochondria leak trace amounts of cytochrome 
c during normal turnover of these organelles, a cell would not necessarily die 
unless enough cytochrome c had been released to support sufficient 
apoptosome-mediated activation of caspase-9 molecules. Even then, it is 
conceivable that activation of caspase-9 might not always signal the end of 
the road for a cell if the level of activity that ensues is not sufficient to activate 
enough executioner caspase-3 or -7 molecules to kill a cell outright and/or 
promote the positive amplification of initial mitochondrial apoptotic events. 
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CHAPTER 5: CASPASE-9 ACTIVATION BY THE APOPTOSOME IS NOT 





Activation of executioner caspases during receptor-mediated apoptosis 
in type II cells requires the engagement of the mitochondrial apoptotic 
pathway.  Although it is well established that recruitment of mitochondria in 
this context involves the cleavage of Bid to tBid, the precise post-
mitochondrial signaling responsible for executioner caspase activation is less 
clear.  Here, we used distinct clones of type II Jurkat T-lymphocytes in which 
the mitochondrial apoptotic pathway had been inhibited to investigate the 
molecular requirements necessary for Fas-induced apoptosis.  Cells 
overexpressing either Bcl-2 or Bcl-xL were protected from apoptosis induced 
by agonistic anti-Fas antibody.  By comparison, Apaf-1-deficient Jurkat cells 
were sensitive to anti-Fas, exhibiting Bid cleavage, Bak activation, the release 
of cytochrome c and Smac, and activation of executioner caspase-3.  
Inhibiting downstream caspase activation with the pharmacological inhibitor 
Z-DEVD-fmk or by expressing the BIR1/BIR2 domains of XIAP decreased all 
anti-Fas-induced apoptotic changes.  Additionally, pretreatment of Bcl-xL-
overexpressing cells with a Smac mimetic sensitized these cells to Fas-
 80
induced apoptosis.  Combined, our findings strongly suggest that Fas-
mediated activation of executioner caspases and induction of apoptosis do 
not depend on apoptosome-mediated caspase-9 activation in prototypical 




Apoptosis is an active form of cell death that is executed by a family of 
cysteine proteases that cleave intracellular substrates after aspartate 
residues (caspases).  Because apoptosis is important for cell removal during 
development and tissue homeostasis, disruptions in the regulation of 
apoptosis can play a role in the onset of numerous pathologies, including 
neurodegenerative disorders, autoimmunity, and cancer (Fadeel et al., 1999).   
 Apoptosis can occur through two distinct signaling pathways.  One is 
the extrinsic (receptor-mediated) pathway in which binding of a death receptor 
(e.g. TNF-R1 and Fas) by a cognate ligand (e.g. TNFα and FasL) or an 
agonistic antibody (e.g. CH-11) causes the recruitment of adaptor proteins 
(e.g. TRADD and FADD) and initiator pro-caspase-8 molecules to the 
cytosolic side of the receptor to form the death-inducing signaling complex 
(DISC) (Kischkel et al., 1995).  Within the DISC, pro-caspase-8 molecules are 
activated by dimerization and subsequently undergo autoprocessing 
(Boatright et al., 2003; Pop et al., 2007).  In most cell types (type I), active 
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caspase-8 activates the executioner caspase-3, which, in turn, is responsible 
for many of the morphological and biochemical manifestations of apoptosis.  
In other cell types (type II), the amount of caspase-8 that is activated within 
the DISC is low and insufficient to directly activate downstream executioner 
pro-caspases, including caspase-3 and -7 (Scaffidi et al., 1998).  Instead, 
active caspase-8 in type II cells is known to cleave the cytosolic BH3-only 
protein Bid to tBid (Li et al., 1998; Luo et al., 1998; Shelton et al., 2009).  In 
turn, tBid can activate a multidomain Bcl-2 family protein (i.e. Bax and Bak) 
that stimulates MOMP and the release of intermembrane space proteins into 
the cytosol (Kim et al., 2006b; Wei et al., 2001).  In this regard, it is now 
widely accepted that the mitochondrial apoptotic pathway plays an important 
role during receptor-mediated death in type II cells (Li et al., 2002; Samraj et 
al., 2006; Scaffidi et al., 1998; Scaffidi et al., 1999; Schmitz et al., 1999; Sun 
et al., 2002; Wilkinson et al., 2004), although conflicting results exist 
regarding the precise molecular signaling requirements.  Some evidence 
obtained using a reconstituted in vitro cell-free system showed that 
recombinant Smac was sufficient to activate caspase-3 activity by inhibiting 
XIAP (Sun et al., 2002).  A different study using type II lymphoid cells 
demonstrated that overexpression of XIAP could inhibit Fas-induced 
apoptosis in wild-type cells, and knocking down XIAP expression could 
sensitize Bcl-xL-transfected cells to receptor-mediated cell killing (Wilkinson et 
al., 2004).  Although the results of these two studies suggested that Smac-
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dependent inhibition of XIAP was the foremost consequence of MOMP during 
extrinsic apoptosis in type II cells, neither one of the studies used an 
experimental system in which a component of the apoptosome was missing.  
Interestingly, a more recent study reported that a caspase-9-deficient clone of 
type II lymphoid cells was highly resistant to Fas-induced caspase activation, 
which, in contrast to the two earlier studies, implicated an essential role for 
cytochrome c-dependent apoptosome formation and the activation of 
caspase-9 during Fas-induced apoptosis (Samraj et al., 2006).  
In this regard, the aim of this study was to clarify the signaling 
requirements necessary for Fas-mediated apoptosis in prototypical type II 
cells.  Because each of the aforementioned studies was performed using 
Jurkat cells, we also used clones of this cell line in which the intrinsic pathway 
had been inhibited due to either stable overexpression of Bcl-2/Bcl-xL, the 
stable depletion of Apaf-1, or the stable expression of the baculoviral inhibitor 
of apoptosis protein repeat 1 and 2 (BIR1/BIR2) domains of XIAP (Shawgo et 
al., 2008).  The data provided direct evidence that apoptosome-mediated 
caspase-9 activation is not required for extrinsic apoptosis induced by anti-
Fas (CH-11).   Instead, our findings suggested that the inhibition of XIAP was 





5.3 Results and Discussion 
 
5.3.1 Bcl-2 or Bcl-xL Overexpression, but Not Apaf-1 Knockdown, Confers 
Resistance to Fas-Induced Apoptosis 
 
Previously, we demonstrated that Jurkat cells, in which either an anti-
apoptotic Bcl-2 family protein had been overexpressed or Apaf-1 had been 
knocked down, were entirely resistant to mitochondria-mediated apoptosis 
(Shawgo et al., 2008).  Here, we were interested in the susceptibility of the 
different cells to receptor-mediated killing induced by agonist anti-Fas 
antibody (CH-11).  As shown in Figure 16A, only control-transfected and 
Apaf-1-deficient cells underwent Fas-induced apoptosis.  Specifically, after 
treatment with a concentration of 100 ng/ml of anti-Fas, vector control and 
Apaf-1-silenced cells displayed ~38% and ~25% apoptosis, respectively, at 6 
h.  By comparison, when the Bcl-2- and Bcl-xL-overexpressing cells were 
incubated under the same conditions they exhibited ~2% and ~4% apoptosis, 
respectively.  In agreement with these findings, Western blot analysis of cell 
lysates revealed that proteolytic processing of caspase-8 was significantly 
more pronounced in wild-type, vector control, and Apaf-1-deficient cells as 
compared to Bcl-2- and Bcl-xL-overexpressing cells (Figure 16B).  That is, 
more of both the cleaved intermediate (p43/p41) and active (p18) fragments 
of caspase-8 were evident after incubation with 100 ng/ml of anti-Fas for 6 h.  
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Figure 16. Bcl-2 or Bcl-xL Overexpression, But not Apaf-1 Knockdown, 
Inhibits Apoptosis in Response to Agonistic anti-Fas Antibody (CH-11). 
(A) Control-transfected, Bcl-xL- and Bcl-2-overexpressing, and Apaf-1-
deficient Jurkat clones (106/ml) were cultured in the presence or absence of 
100 ng/ml anti-Fas for 6 h, harvested, and processed for cell death 
determination by flow cytometric analysis of annexin V-FITC and propidium 
iodide (PI) staining. Quadrants are defined as: live (lower left); early apoptotic 
(lower right); late apoptotic (upper right); and necrotic (upper left). Numbers 
refer to the percentage of cells in each quadrant. (B) Duplicate aliquots of 
cells were harvested and lysed for Western blotting. (C) Bcl-xL- and Bcl-2-
overexpressing cells were cultured in the presence of 100 ng/ml anti-Fas for 
24 h, harvested, and processed for cell death determination as described in 
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Similarly, cleavage of Bid to tBid and the processing of caspase-3 to its fully 
active p19/p17 fragments occurred in the wild-type, vector control, and Apaf-
1-deficient cells (Figure 16B, lanes 2, 8, and 10).  By comparison, only the 
p20 caspase-3 intermediate fragment was observed in the Bcl-xL- and Bcl-2-
overexpressing cells (Figure 17B, lanes 4 and 6) suggesting that normal 
caspase-3-mediated autocatalytic removal of the N-terminal prodomain had 
been impaired (Han et al., 1997; Liu et al., 2005), presumably due to inhibition 
by an IAP (Riedl et al., 2001b).  Cleavage of caspase-9 occurred in four out of 
the five cell lines, although producing two fragments (p37/p35) in wild-type 
and control-transfected cells, and only one fragment (p37) in Apaf-1-deficient 
and Bcl-xL-overexpressing cells (Figure 16B, lanes 2 and 8 versus lanes 4 
and 10).  This is important because apoptosome-mediated activation and self-
cleavage of caspase-9 has been reported to occur after Asp315 yielding a p35 
fragment, whereas the appearance of the catalytically inactive p37 fragment 
(Denault et al., 2007) is most often linked to caspase-3-mediated cleavage of 
caspase-9 after Asp330 (Srinivasula et al., 1998).  The small amount of p37 
caspase-9 that was produced in the anti-Fas-treated Bcl-xL-overexpressing 
cells could be due to a trace amount of autocatalytic processing of p20 
caspase-3 to p19 caspase-3 that had occurred (Figure 16B, lane 4).  
Nevertheless, as shown in Figure 16C, both Bcl-2- and Bcl-xL-overexpressing 
cells were refractory to receptor-mediated apoptosis even after 24 h of 
incubation with anti-Fas.  Combined, Bcl-2- and Bcl-xL-overexpressing cells 
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are highly resistant to apoptosis induced by anti-Fas antibody, whereas cells 
with impaired apoptosome function and thus caspase-9 activation remain 
highly susceptible to this form of cell killing. 
 
5.3.2 Sensitivity of Apaf-1-Deficient Jurkat Cells to anti-Fas Treatment is 
Associated with Extensive Mitochondrial Apoptotic Changes 
 
As mentioned previously, Fas-mediated apoptotic signaling in type I 
cells is generally thought to occur by active caspase-8 directly cleaving and 
activating caspase-3, whereas recruitment of the intrinsic (mitochondria-
mediated) pathway is widely thought to be essential for Fas-mediated 
apoptosis in type II cells.  Because our different gene-manipulated Jurkat cell 
clones with impaired intrinsic pro-apoptotic signaling were so markedly 
dissimilar in their sensitivity to apoptosis induced by anti-Fas, we sought to 
investigate the extent to which this might be due to differences in 
mitochondrial events.  Thus, we first evaluated the different cells for changes 
in Δψ.   Vector control and Apaf-1-deficient cells underwent a drop in Δψ 
when incubated in the presence of anti-Fas for 6 h (Figure 17A), and it is 
worth noting that Apaf-1-deficient cells were resistant to Δψ loss when 
incubated in the presence of etoposide (Franklin and Robertson, 2007).   In 
contrast, overexpression of either Bcl-xL or Bcl-2 rendered cells totally 
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Figure 17. Fas-Induced Apoptosis in Apaf-1-Deficient Cells is 
Accompanied by Extensive Mitochondrial Events. 
(A) Control-transfected, Bcl-xL- and Bcl-2-overexpressing, and Apaf-1-
deficient Jurkat clones (106/ml) were cultured in the absence or presence of 
100 ng/ml anti-Fas for 6 h and processed for mitochondrial membrane 
potential (ΔΨ) determination by flow cytometry.  Reduced DiIC1(5) 
fluorescence is indicative of a loss of ΔΨ, and numbers refer to the 
percentage of cells that underwent a dissipation of ΔΨ. (B) Duplicate aliquots 
of cells were harvested and processed for subcellular fractionation. 
Supernatant (s) and pellet (p) fractions were analyzed by Western blotting. (C 
and D) Wild-type, control-transfected, Bcl-xL- and Bcl-2-overexpressing, and 
Apaf-1-deficient Jurkat clones (106/ml) were cultured in the absence or 
presence 100 ng/ml anti-Fas for 6 h and processed for determination of Bak 
oligomerization by Western blotting (C) or Bak activation by flow cytometric 
analysis (D). In panel D histograms show Bak-associated fluorescence in 
vehicle-treated (filled histograms) and apoptotic stimulus-treated (open 
histograms) cells after 6 h, and numbers refer to the percentage increase in 
mean fluorescence intensity. shRNA, short hairpin RNA; BMH, 
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refractory to any loss of Δψ induced by anti-Fas.  Because a drop in Δψ is 
often associated with the release of mitochondrial intermembrane space 
proteins into the cytosol, we next investigated whether the release of 
cytochrome c and Smac had occurred in the different cell types.  Treatment 
with anti-Fas led to a pronounced release of cytochrome c and Smac from 
vector control and Apaf-1-deficient cells (Figure 17B) consistent with the Δψ 
data.   
To investigate the extent to which differences in the release of 
cytochrome c and Smac corresponded to differences in the activation of Bak 
(E6.1 cells do not express Bax (Shawgo et al., 2008; Shelton et al., 2009)) we 
used two different techniques. We first investigated whether Bak underwent 
oligomerization using the cross-linking agent BMH.  As illustrated in Figure 
17C, cross-linked Bak protein complexes were observed in wild-type and 
control-transfected Jurkat cells treated with 100 ng/ml of anti-Fas for 6 h.  In 
line with the mitochondrial apoptotic changes that were observed (Figure 17A 
and B), dimerization and activation of Bak were detected in wild-type, vector 
control, and Apaf-1-deficient Jurkat cells, whereas cells overexpressing Bcl-2 
or Bcl-xL were resistant to changes in Bak status (Figure 17C).    These 
findings were in agreement with results obtained using an active 
conformation-specific monoclonal Bak antibody and flow cytometric analysis, 
where Bak activation amounts to a shift to the right in the resulting histogram 
(Figure 17D).  Specifically, vector control and Apaf-1-deficient cells exhibited 
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large increases in Bak-associated fluorescence of 280 and 300%, 
respectively, whereas Bcl-xL and Bcl-2 cells displayed more modest increases 
of 50 and 20%, respectively.  Collectively, these findings suggest that the 
sensitivity of cells with Apaf-1-deficient cells to Fas-induced apoptosis is due, 
at least in part, to that fact that these cells undergo MOMP. 
 
5.3.3 Caspase-3/7 (DEVDase) Activity Mediates the Majority of Fas-Mediated 
Apoptotic Events in Apaf-1-Deficient Cells 
 
As mentioned, stimulation of the Fas receptor with its corresponding 
ligand or an agonistic antibody leads to formation of the DISC and activation 
of caspase-8 by dimerization (Boatright et al., 2003).  Because of existing 
evidence indicating that the amount of caspase-8 that is activated at the DISC 
in type II cells is too low to efficiently cleave and activate caspase-3 (Scaffidi 
et al., 1999), it is widely believed that caspase-8 cleaves Bid to tBid, which, in 
turn, recruits the intrinsic (mitochondria-mediated) apoptotic pathway by 
activating Bax or Bak.  In this regard, it is thought that type II cells rely heavily 
on the intrinsic pathway for receptor-mediated apoptosis (Samraj et al., 2006; 
Scaffidi et al., 1998; Scaffidi et al., 1999; Schmitz et al., 1999).  However, 
such a model would not explain why the Apaf-1-deficient cells, which cannot 
activate caspase-9 (p35) in response to intrinsic (Franklin and Robertson, 
2007; Shawgo et al., 2008) or extrinsic (Figure 16B, lane 9 versus 10) stimuli, 
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are sensitive to Fas-mediated apoptosis, exhibiting Bak activation (Figure 
17C and D), induction of MOMP (Figure 17B), and the robust cleavage of 
caspase-8 to its intermediate (p43/p41) and active (p18) fragments (Figure 
16B, lane 9 versus 10).     
 Because caspase-3 was also cleaved to its fully active p19/p17 
fragments in cells lacking Apaf-1 (Figure 16B, lane 9 versus 10), we 
investigated the potential importance of caspase-3/7 in producing the various 
apoptotic changes in anti-Fas-treated Apaf-1-deficient cells.  To that end, we 
incubated cells with the caspase inhibitor Z-DEVD-fmk (25 µM) for 1 h prior to 
treatment with anti-Fas (100 ng/ml) for 6 h.  As illustrated, Z-DEVD-fmk pre-
treatment prevented Fas-induced autocatalytic cleavage of caspase-3 to its 
fully active p19/p17 fragments, whereas it was not able to eliminate the 
generation of the p20 caspase-3 intermediate fragment by caspase-8 (Figure 
18A, lanes 2 versus 3, 5 versus 6, and 8 versus 9).  Pre-treatment of cells 
with Z-DEVD-fmk dramatically reduced the appearance of the p43/p41 
fragments of caspase-8 suggesting that most of the Fas-mediated cleavage 
of pro-caspase-8 occurs downstream of caspase-3/7 activation (Figure 18A).  
In addition, Z-DEVD-fmk markedly inhibited the appearance of tBid (Figure 
18A), arguing strongly that the majority of Fas-induced Bid cleavage occurs 
downstream, or independently, of the low level of caspase-8 activity that 
occurs initially during receptor-mediated apoptosis in type II Jurkat cells.  Z-
DEVD-fmk also inhibited the processing of caspase-9 (Figure 18A).  
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Figure 18. Requirement of Caspase-3/7 (DEVDase) Activity for Fas-
Induced Apoptotic Changes in Apaf-1-Deficient Cells. 
(A) Wild-type, control-transfected, and Apaf-1-deficient Jurkat cells (106/ml), 
pre-incubated with or without 25 μM Z-DEVD-fmk for 1 h, were incubated with 
100 ng/ml anti-Fas for 6 h, harvested and lysed for Western blotting. (B-E) 
Duplicate aliquots of cells were harvested and processed for cell death 
determination by flow cytometric analysis of annexin V-FITC and propidium 
iodide staining (B), Bak oligomerization and activation (C), determination by 
flow cytometric analysis of DiIC1(5) associated fluorescence (D), and 
subcellular fractionation followed by Western blotting of supernatant (s) and 
pellet (p) fractions (E). In panel (B), quadrants are defined as: live (lower left), 
early apoptotic (lower right), late apoptotic (upper right), and necrotic (upper 
left). Numbers refer to the percentage of cells in each quadrant. In panel (D), 
numbers refer to the percentage of cells that underwent a dissipation of ΔΨ. 
shRNA, short hairpin RNA; Casp, caspase; BMH, bismaleimidohexane; Z-
DEVD-fmk; Z-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-CH2F; Cyt c, cytochrome 
c; ΔΨ, mitochondrial membrane potential. 
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Specifically, the appearance of the p37 fragment of caspase-9 was largely 
prevented by pre-treatment with Z-DEVD-fmk.  As mentioned previously, the 
p37 fragment of caspase-9, which lacks proteolytic activity (Denault et al., 
2007), is generated by caspase-3-mediated proteolysis, whereas the p35 
fragment of caspase-9 is produced by apoptosome-mediated dimerization 
and autocatalysis (Srinivasula et al., 1998).  As anticipated, Z-DEVD-fmk also 
blocked Fas-induced apoptosis as determined by annexin V-FITC 
fluorescence (Figure 18B).  
 We next examined the effect of Z-DEVD-fmk on Fas-induced 
mitochondrial apoptotic events.  As shown, pre-treatment of cells with Z-
DEVD-fmk partially inhibited Bak oligomerization (Figure 18C), the loss of Δψ 
(Figure 18D), and the release of cytochrome c and Smac (Figure 18E) 
induced by anti-Fas.  Taken together, these data suggest that many of the 
observable apoptotic changes induced by anti-Fas treatment are mediated by 
caspase-3/7 (DEVDase) activity.  In addition, these findings support a model 
of receptor-mediated apoptosis in which the intrinsic pathway per se is not 






5.3.4 Expression of the BIR1/BIR2 Domains of XIAP Inhibits Fas-Induced 
Apoptosis 
 
Because Z-DEVD-fmk pre-treatment inhibited to a similar extent Fas-
induced apoptotic changes in wild-type, vector control, and Apaf-1-deficient 
cells, and because of concerns about the specificity of so-called specific 
peptide-based caspase inhibitors, including Z-DEVD-fmk (McStay et al., 
2008), we next took a genetic approach to inhibiting downstream caspases.  
Specifically, we examined the sensitivity of Jurkat cells engineered to stably 
express the BIR1/BIR2 domains of XIAP (Shawgo et al., 2008) to Fas-
induced apoptosis.  XIAP belongs to the inhibitor of apoptosis protein family 
(Deveraux et al., 1997) and a region of this protein that includes the BIR2 
domain is known to inhibit caspase-3 and -7 (Chai et al., 2001; Riedl et al., 
2001b; Scott et al., 2005).     
 As illustrated in Figure 19A, vector control cells underwent apoptosis 
(~40%) when incubated with anti-Fas (100 ng/ml) for 6 h, whereas the 
BIR1/BIR2 transfectants exhibited significantly less apoptosis (~14%).  In 
agreement with these findings, Western blot analysis of cell lysates generated 
at 6 h after incubation with anti-Fas showed that extensive proteolytic 
processing of caspase-8, -9, -3, and -7 had occurred in vector control cells, 
whereas caspase processing in cells expressing the BIR1/BIR2 domains of 
XIAP was markedly reduced (Figure 19B). 
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Figure 19. BIR1/BIR2-Expressing Jurkat cells are Resistant to Early and 
Late Fas-Induced Apoptotic Changes. 
(A) Control-transfected and Myc-BIR1/BIR2-overexpressing Jurkat cells were 
incubated in the presence or absence of 100 ng anti-Fas for 6 h and 
processed for cell death determination by flow cytometric analysis of annexin-
V-FITC and propidium iodide staining. Quadrants are defined as live (lower 
left), early apoptotic (lower right), late apoptotic (upper right), and necrotic 
(upper left). Numbers refer to the percentage of cells in each quadrant. (B) 
Duplicate aliquots of cells in (A) were harvested and lysed for Western 
blotting (B). (C) Duplicate aliquots of cells in (A) were processed for 
mitochondrial membrane potential (ΔΨ) determination by flow cytometry. 
Reduced DiIC1(5) fluorescence is indicative of loss of ΔΨ, and numbers refer 
to the percentage of cells that underwent a dissipation of ΔΨ. (D) Duplicate 
aliquots of cells in A were processed for subcellular fractionation followed by 
Western blotting of supernatant (s) and pellet (p) fractions. (E) Duplicate 
aliquots of cells in A were processed for Bak oligomerization by Western 












































































































































Next, we determined whether Fas-induced mitochondrial events were altered 
in BIR1/BIR2-expressing cells.  As shown in Figure 19C, treatment of cells 
with anti-Fas for 6 h resulted in nearly half (~42%) of the control-transfected 
cells displaying a loss of Δψ, while cells expressing the BIR1/BIR2 domains of 
XIAP underwent a more modest drop in Δψ of ~12%.  Similar findings were 
obtained with respect to MOMP induction as measured by Western blot 
analysis of cytochrome c and Smac release into the cytosol (Figure 19D, lane 
2 versus 1 and lane 4 versus 3).  Finally, we were interested to investigate 
whether the maintenance of Δψ and reduced MOMP in the BIR1/BIR2-
expressing cells corresponded with decreased Bak activation.  As shown in 
Figure 19E, Fas-induced Bak activation was attenuated in cells expressing 
the BIR1/BIR2 domains of XIAP.  Overall, these findings support and extend 
the results presented in Figure 18 and offer genetic evidence that executioner 
caspases play an important role in eliciting MOMP in response to anti-Fas in 
type II cells.        
   
5.3.5 A Smac Mimetic Partially Sensitizes Bcl-xL-Overexpressing Cells to Fas-
Induced Apoptosis 
  
Because the p20 fragment of caspase-3 was detected uniformly in (i) 
anti-Fas-treated Apaf-1-deficient cells that had been pre-incubated with Z-
DEVD-fmk (Figure 18A), (ii) cells made to express the BIR1/BIR2 domains of 
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XIAP (Figure 19B), and (iii) Bcl-xL-overexpressing cells incubated with anti-
Fas alone (Figure 16B), we speculated that the reason p20 caspase-3 was 
not able to undergo autocatalysis to its p19/p17 fragments in cells 
overexpressing Bcl-xL might be due to persistent inhibition of its enzyme 
activity by an IAP, such as XIAP, as reported previously in vitro (Sun et al., 
2002).  Smac, which is a protein that is normally sequestered in the 
mitochondrial intermembrane space, is released together with cytochrome c 
in response to various apoptotic stimuli (Du et al., 2000; Verhagen et al., 
2000) and binds to and inhibits XIAP by targeting XIAP’s second baculoviral 
inhibitory repeat (BIR) domain (Chai et al., 2000; Srinivasula et al., 2001; Wu 
et al., 2000).  In this respect, Smac is considered to be a derepressor of 
caspase inhibition by XIAP, and several cell-permeable Smac mimetics have 
been designed that can potentiate pro-apoptotic stimuli (Li et al., 2004; Park 
et al., 2005; Sun et al., 2004; Wu et al., 2003) as well as induce apoptosis 
independently (Petersen et al., 2007).  
To test the extent to which Smac could sensitize Bcl-xL-overexpressing 
cells to anti-Fas, we obtained a Smac mimetic (compound 3) that was shown 
previously to bind XIAP (also cellular IAP 1(cIAP1) and cIAP2) and act 
synergistically with TRAIL or TNFα to induce apoptosis in cancer cell lines 
that are normally resistant to these two receptor stimuli (Li et al., 2004).  In 
agreement with findings from that study, incubation of cells with 100 nM 
compound 3 for up to 16 h did not induce apoptosis (data not shown) or 
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proteolytic processing of caspase-8 (Figure 20B).  However, when Bcl-xL-
overexpressing cells were pre-treated with 100 nM compound 3 for 4 h and 
subsequently incubated with anti-Fas (100 ng/ml) for 12 h, ~11% of cells 
underwent apoptosis compared to ~25% of control-transfected cells incubated 
with anti-Fas alone (Figure 20A).  Likewise, when used in combination with 
anti-Fas, compound 3 caused enhanced proteolytic cleavage of caspase-8 as 
well as the generation of some of the p19/p17 fully active fragments of 
caspase-3 in Bcl-xL-overexpressing cells (Figure 20B).  Alternatively, it could 
be that the Smac mimetic can partially sensitize Bcl-xL-overexpressing cells to 
anti-Fas through a caspase-8-dependent mechanism that involves TNF-α 
autocrine signaling (Petersen et al., 2007; Varfolomeev et al., 2007; Vince et 
al., 2007). However, this seems unlikely since incubation of cells with the 
Smac mimetic alone did not cause caspase proteolysis or an induction of 
apoptosis.  Combined, these findings suggest that Smac release is important 
for receptor-mediated activation of executioner caspases and death in Jurkat 
cells insofar as Smac may be needed to alleviate caspase inhibition by an 
IAP.   
 
5.4 Concluding Remarks 
 
Type II cells are distinguished from type I cells by their reliance on the 
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Figure 20. A Smac Mimetic (Compound 3) Synergizes with anti-Fas 
Antibody to Induce Apoptosis in Bcl-xL-Overexpressing Cells. 
(A) Control-transfected and Bcl-xL-overexpressing cells (10
6/ml) were 
incubated in the absence or presence of 100 nM Smac mimetic (compound 3) 
for 4 h and/or anti-Fas for 12 h, harvested, and processed for cell death 
determination by flow cytometric analysis of annexin V-FITC and propidium 
iodide staining. Quadrants are defined as: live (lower left), early apoptotic 
(lower right), late apoptotic (upper right), and necrotic (upper left). Numbers 
refer to the percentage of cells in each quadrant. (B) Duplicate aliquots were 
harvested and lysed for Western blotting. Asterisk denotes nonspecific band. 
Casp, caspase. 
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apoptosis induced by a death ligand (e.g. FasL or TNFα) or an agonistic 
antibody (e.g. CH-11).  The proposed need for the intrinsic pathway in type II 
cells centers around the fact that formation of the DISC is impaired in these 
cells and that the low level of active caspase-8 that is produced within the 
DISC is sufficient only to cleave the BH3-only protein Bid.  In turn, tBid 
activates a multidomain Bcl-2 protein, Bax or Bak, leading to the recruitment 
of the mitochondrial pathway.  The strongest evidence supporting the 
existence of a two-pathway receptor-mediated model of apoptosis is that 
overexpressing a suppressor of the intrinsic pathway, notably Bcl-2 or Bcl-xL, 
protects against apoptosis in some cell types (type II) but not others (type I) 
(Scaffidi et al., 1998; Scaffidi et al., 1999; Schmitz et al., 1999).  However, 
recent studies examining the type I/II paradigm in lymphoid cells have 
produced conflicting results (Samraj et al., 2006; Sun et al., 2002; Wilkinson 
et al., 2004).  The primary point of contention is the extent to which 
mitochondrial involvement is truly necessary for receptor-mediated 
executioner caspase activation and apoptosis in type II cells.         
Our findings, using apoptosome-deficient cells incapable of activating 
caspase-9, provide direct evidence that the mitochondrial apoptotic pathway 
per se is not essential for Fas-induced apoptosis in type II cells.  In particular, 
we have demonstrated that Apaf-1-deficient Jurkat cells, which are equally 
resistant to etoposide-induced apoptosis as Jurkat cells overexpressing Bcl-2 
or Bcl-xL (Shawgo et al., 2008), are highly susceptible to receptor-mediated 
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apoptosis.  Although the sensitivity of Apaf-1-deficient cells to anti-Fas 
treatment was associated with extensive cleavage of Bid and induction of 
MOMP, the resulting release of intermembrane space proteins failed to 
activate caspase-9.  Additionally, our findings indicated that Fas-induced 
cleavage of Bid depends to a large extent on DEVDase activity and/or occurs 
downstream of caspase-3/7 activation.  However, it is possible that the initial 
cleavage of Bid by caspase-8 occurs at a level that is not detectable by 
Western blotting but is nevertheless sufficient to cause Bak-mediated MOMP 
in cells other than those overexpressing Bcl-2 or Bcl-xL.  Indeed, estimates 
have indicated that miniscule amounts of tBid are all that is needed to induce 
Bax/Bak-dependent cytochrome c release in some settings (Zha et al., 2000).  
In this way, it could be that the portion of Bid that appears to be cleaved 
downstream of caspase-3/7 activation functions to positively amplify MOMP in 
response to Fas and seal a cell’s fate (Shelton et al., 2009).   
Because cytochrome c release following MOMP appeared to be 
dispensable for Fas-induced apoptosis in Apaf-1-deficient cells, since it did 
not lead to the formation of a functioning apoptosome, we hypothesized that 
Smac release might function in this context to promote executioner caspase 
activity by inhibiting an IAP, as reported previously for XIAP using in vitro cell-
free systems (Sun et al., 2002).  Indeed, we found that a cell-permeable 
Smac mimetic was able to partially sensitize Bcl-xL-overexpressing cells to 
Fas-induced apoptosis.  This finding, in part, might help reconcile our results 
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with those of Samraj et al. (Samraj et al., 2006).  In that study, the authors 
reported that a caspase-9-deficient clone of Jurkat cells they had identified 
was strongly resistant to Fas-mediated apoptosis, despite undergoing MOMP 
as indicated by cytochrome c release.  However, no mention of whether 
Smac was released together with cytochrome c was included, and some 
evidence suggests the release of these proteins can be differentially 
regulated (Adrain et al., 2001; Kandasamy et al., 2003).  In this regard, it 
would be of particular interest to know whether a Smac mimetic could 
sensitize those caspase-9-deficient cells to Fas-induced apoptosis.  In our 
case, the fact that the Smac mimetic-induced sensitization of Bcl-xL-
overexpressing cells to anti-Fas was not more pronounced suggests that the 
release of other mitochondrial factors, such as Omi, may contribute 
significantly toward alleviating the suppressive effects of IAPs.  Alternatively, 
it is possible that Bcl-xL can exert anti-apoptotic functions in the cell that are 
separate from its established ability to inhibit MOMP.  Overall, these findings 
support a model of Fas-mediated apoptosis in type II cells in which the main 
function of the intrinsic pathway is to inhibit IAP-mediated inhibition of 
caspase-3/7, rather than to activate caspase-9 and/or executioner caspases 
directly. 
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CHAPTER 6: APAF-1 DEFICIENCY PROMOTES THE ELIMINATION OF 
CYTOCHROME C AND SMAC BY PROTEASOMAL DEGRADATION, AND 





Within the existing paradigm of genotoxic stress-induced apoptosis, 
the intrinsic apoptotic pathway is thought to proceed in a linear fashion.  Apaf-
1 is a critical component of the intrinsic pathway that is generally thought to 
reside downstream of MOMP.  However, our laboratory reported previously 
that Apaf-1-deficient Jurkat T-lymphocytes do not release cytochrome c or 
activate Bak following a short incubation (6 h) with the DNA-damaging drug 
etoposide. In the current study, we show that the same Apaf-1-deficient cells 
were resistant to etoposide-induced apoptosis up to 24 h.  Surprisingly, total 
cellular cytochrome c and Smac were markedly decreased after 24 h of 
incubation.  A closer examination of the cellular response revealed that 
etoposide-treated Apaf-1-deficient cells displayed subtle biochemical markers 
of autophagy and co-incubating cells with an autophagy inhibitor, 3-
methyladenine, partially retained total cellular cytochrome c and Smac.  At the 
same time, etoposide-treated Apaf-1-deficient cells underwent some MOMP 
as evidenced by Bak activation and trace cytochrome c release beginning at 
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8 h.  Interestingly, inhibition of the 26S proteasome by pretreatment of Apaf-1-
deficient cells with bortezomib or MG132 led to the robust retention of total 
cellular cytochrome c and Smac.  Combined, these data suggest that 
proteasomal degradation, and to a lesser extent autophagy, are responsible 
for the loss of intracellular cytochrome c and Smac in the Apaf-1-deficient 




Mitochondria-mediated apoptosis (intrinsic pathway) is a form of cell 
death that is critical for eliminating cells with irreparable DNA damage (Chipuk 
et al., 2006; Letai, 2009; Letai et al., 2002)  Disruptions in control of the 
mitochondrial apoptotic pathway can facilitate tumorigenesis as well as 
contribute to the resistance of cancer cells to antineoplastic therapy (Green 
and Kroemer, 2005; Johnstone et al., 2002).  In addition, many cancer 
chemotherapy drugs, including etoposide, are effective against malignancies 
due to their ability to induce intrinsic apoptosis.   
Within the current model of genotoxic stress-induced apoptosis, the 
intrinsic apoptotic pathway progresses in a linear fashion (Chipuk et al., 2006; 
Goldstein et al., 2005; Goldstein et al., 2000; Waterhouse et al., 2001).  This 
pathway is generally thought to begin with the homo-oligomerization and 
activation of a multidomain pro-apoptotic Bcl-2 protein (i.e. Bax and/or Bak) 
(Chipuk and Green, 2006; Ow et al., 2008), which depends on the prior 
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activation of a BH3-only protein, such as tBid, Bim, Puma, Noxa, and Bad.  
Monomeric, inactive Bax resides in the cytosol and has to move to the 
mitochondrial outer membrane, whereas monomeric, inactive Bak is normally 
loosely associated with the outer mitochondrial membrane (Cheng et al., 
2001; Chipuk et al., 2006; Scorrano and Korsmeyer, 2003; Wei et al., 2001).  
Homo-oligomerization and activation of Bax and/or Bak allows the formation 
of pores in the mitochondrial outer membrane (Chipuk et al., 2006; Ow et al., 
2008), which, in turn, permits the release of pro-apoptotic factors (e.g. 
cytochrome c and Smac) into the cytosol (Cartron et al., 2004; Chipuk et al., 
2006; Desagher et al., 1999; Kuwana et al., 2005; Kuwana et al., 2002; Luo et 
al., 1998; Marani et al., 2002; Scorrano and Korsmeyer, 2003).  Anti-apoptotic 
Bcl-2 family proteins, such as Bcl-2 and Bcl-xL, reside on the mitochondrial 
outer membrane and prevent the cell from undergoing MOMP by binding and 
inhibiting Bax/Bak directly (Chen et al., 2005; Willis et al., 2007) or by 
sequestering a BH3-only protein (Kim et al., 2006a).  MOMP is generally 
thought to be the “point of no return” within the intrinsic pathway, meaning 
that the cells are unable to recover from MOMP (Green and Kroemer, 2004; 
Kroemer and Reed, 2000). Once released from the mitochondria, these pro-
apoptotic factors promote the activation of caspases. When cytochrome c is 
released into the cytosol it will bind Apaf-1 (Zou et al., 1999).  Subsequently, 
Apaf-1 can alter its conformation and then linearize to allow the binding of 
dATP (Kim et al., 2005).  Next, Apaf-1 olgerimerizes to form a seven-spoked 
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wheel apoptosome complex that, in turn, recruits and promotes the activation 
of initiator pro-caspase-9 protein (Acehan et al., 2002; Boatright et al., 2003; 
Chao et al., 2005; Pop et al., 2006; Rodriguez and Lazebnik, 1999; Shiozaki 
et al., 2002; Srinivasula et al., 1998). Active caspase-9, in turn, activates 
caspase-3/7 to execute cell death (Fuentes-Prior and Salvesen, 2004). Often, 
inhibitors of apoptosis (IAPs) bind to and inhibit partially activated caspase-3, 
-7, and -9 (Chai et al., 2001; Huang et al., 2001; Takahashi et al., 1998).  
Smac helps to activate caspase-3, -7, and -9 by alleviating any inhibition IAPs 
have on caspase-3, -7, and -9 (Shiozaki et al., 2003; Srinivasula et al., 2000).   
Apaf-1 is a critical component of the intrinsic pathway that, in most 
settings, is thought to function strictly downstream of MOMP.  However, our 
laboratory reported that Apaf-1-deficient Jurkat T-lymphocytes do not release 
cytochrome c or lose ΔΨ in response to short-term incubation with the DNA-
damaging drug etoposide (Franklin and Robertson, 2007; Shawgo et al., 
2008).  These events are considered to be upstream of Apaf-1 involvement.  
The aim of this study was to determine the effects of prolonged incubation 
with etoposide (> 6 h) on Apaf-1-deficient cells.  Specifically, which, if any, 
mitochondrial apoptotic events occurred?  The results indicated that total 
cellular cytochrome c and Smac disappear from cells deficient in Apaf-1 after 
prolonged (24 h) treatment with etoposide.  Although some evidence 
suggested that the depletion of cytochrome c and Smac could be due, in part, 
to autophagic removal of mitochondria, other findings indicated that a larger 
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percentage of their disappearance was due to proteolytic degradation by the 
26S proteasome. 
 
6.3 Results and Discussion  
 
6.3.1 All Gene-Manipulated Cells are Resistant to Etoposide Up to 24 h  
 
Recently, our lab published that mitochondria-mediated apoptotic 
events such as release of cytochrome c (Franklin and Robertson, 2007) and 
Bak activation are inhibited in Apaf-1-deficient cells after treatment with 
etoposide for 6 h (Shawgo et al., 2008).  We also suggest that “downstream” 
events in the intrinsic pathway are essential for MOMP after treatment with 
etoposide.  Specifically, effector caspases and Bid form an important feed 
forward amplification loop to fully activate the intrinsic pathway (Shelton et al., 
2009). According to the model, a small amount of pro-apoptotic factors are 
released into the cytosol initially in response to DNA damage. The stimulus 
remains sublethal as long as it does not lead to sufficient apoptosome-
dependent activation of caspase-9 to activate caspase-3/7.  In turn, caspase-
3/7 can cleave Bid to tBid to activate a feed forward amplification loop to seal 
a cell’s fate.  
Here, we were interested in determining whether these cells were 
resistant to etoposide over longer durations of treatment or if apoptosis 
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induction was just delayed.  If apoptosis were merely delayed, it would 
suggest that the feed-forward loop between the mitochondria and 
downstream caspase activation functions as an amplification loop.  If, on the 
other hand, the cells were resistant to DNA-damaging drugs at later time-
points, it would suggest that the feed-forward loop is essential. 
To investigate these two possibilities, we first determined whether 
Apaf-1-deficient cells, as well as cells in which the intrinsic pathway had been 
blocked due to Bcl-2 or Bcl-xL overexpression, were resistant to apoptosis 
induced by etoposide at time-points longer than 6 h.  Cells were incubated 
with etoposide for 0, 4, 8, 16 or 24 h.  The time-course was halted at 24 h 
because this represents the doubling time for Jurkat cells.  After treatment, 
cells were harvested for flow cytometry.  Specifically, we probed for 
externalized phosphatidylserine on the plasma membrane and cell membrane 
permeabilization by co-staining with annexin V-FITC and propidium iodide. 
Compared to the vector control cells that initially had 1% of the cells that were 
apoptotic to over 61% of the cells over the time course of treatment (Figure 
21A top row), the Bcl-xL-and Bcl-2-overexpressing cells were resistant to 
treatment with etoposide up to 24 h (3% and 3%, respectively; Figure 21A, 2nd 
and 3rd rows). Similarly, only 6% of the Apaf-1-deficient cells underwent 
apoptosis at the longest time-point of 24 h (Figure 21A, bottom row).  These 
data suggest that apoptosis is not merely delayed, but actually inhibited, in 
the Apaf-1-deficient cells. These data also  
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Figure 21. Inhibition of the Intrinsic Pathway by Bcl-2/Bcl-xL 
Overexpression or Apaf-1 Depletion Protects Against Etoposide-
Induced Apoptosis up to 24 h. 
A, vector control, Bcl-xL-, and Bcl-2-overexpressing, and Apaf-1-deficient 
Jurkat clones (5 x 105/ml) were cultured with DMSO or etoposide (10 μM) for 
up to 24 h and processed for cell death determination by flow cytometric 
analysis of annexin V-FITC and propidium iodide staining.  Quadrants are 
defined as: live (lower left); early apoptotic (lower right); late apoptotic (upper 
right); and necrotic (upper left).  Numbers refer to the percentage of cells in 
each quadrant.  B, duplicate aliquots of cells in A were harvested and lysed 
for Western blot analysis. shRNA, short hairpin RNA;  Casp, caspase;  pro, 
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suggest that the Apaf-1-deficient cells are similarly resistant to etoposide up 
to 24 h as the Bcl-xL- and Bcl-2-overexpressing cells.   
Next, we examined whether caspase processing was also inhibited up 
to 24 h after etoposide treatment. As early as 4 h post-etoposide treatment in 
the vector control cells, processing of caspase-9, and -7, and the 
disappearance of the pro-form of caspase-6 were observed.  Caspase-3 
processing appeared after 8 h of etoposide treatment in the vector control cell 
line (Figure 21B, lanes 2-5).  The Bcl-xL- and Bcl-2-overexpressing cells 
lacked any caspase processing up to 24 h (Figure 21B, lanes 6-15).  These 
data (Figure 21B) complement the data (Figure 21A), where only 3% of the 
cells were apoptotic. Even though the Apaf-1-deficient cells did not undergo 
death shown by annexin/propidium staining, they did exhibit minor caspase 
processing. In particular, the pro-form of caspase-9 disappeared and the 
inactive p37 fragment  appeared (Denault et al., 2007) (Figure 21B, lanes 16-
20), which is a cleavage event that can be mediated by caspase-3 after 
cleavage at the amino acid Asp330  (Srinivasula et al., 1998).  However, 
because caspase-3 activation did not occur (Figure 21B, lane 20) to an 
appreciable extent in Apaf-1-deficient cells, it raises the possibility that other 
intracellular proteolytic activity is responsible for procaspase-9 cleavage.  
Additionally, there was disappearance of the pro-form of caspase-7 but no 
appearance of the active p20 fragment at 24 h with etoposide treatment 
(Figure 21B, lane 20).  Lastly, a small amount of the pro-form of caspase-6 
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also disappeared (Figure 21B, lane 20).  Even though none of the caspases 
were cleaved completely, indicating no fully activated caspases, our findings 
suggest that some amount of caspase activity was present in the Apaf-1-
deficient cells insofar as caspases are known to be effective substrates for 
one another.  
 
6.3.2 No Classical Mitochondrial Apoptotic Events in Gene-Manipulated 
Jurkat Cell lines After 24 h with Etoposide Treatment  
 
The loss of ΔΨ is a common occurrence in cells undergoing intrinsic 
apoptosis.  Thus, we next examined whether drug-resistant cells incubated 
with etoposide for 24 h had lost ΔΨ as determined by staining with DilC1(5).  
This dye accumulates in cells with normal ΔΨ but not in those cells that have 
lost ΔΨ.  As illustrated in Figure 22A (top row), vector control cells 
experienced a robust loss of ΔΨ, whereas neither Bcl-2/Bcl-xL-
overexpressing or Apaf-1-deficient cells underwent a significant loss of ΔΨ.  
However, in the case of the Apaf-1-deficient cells, it is worth noting that, 
although mitochondria remained coupled on the whole, there was some 
heterogeneity in this response as illustrated by the peak flattening somewhat.  
In agreement with these results, incubation of vector control cells with 
etoposide (10 μM) caused a time-dependent release of cytochrome c and  
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Figure 22. Classical Mitochondrial Apoptotic Events are Inhibited in 
Apaf-1-Deficient and Bcl-2/Bcl-xL-Overexpressing Jurkat Cells After 24 h 
of Etoposide Treatment. 
A, vector control, Bcl-xL- and Bcl-2-overexpressing, and Apaf-1-deficient 
Jurkat clones (5 x 105/ml) were cultured with DMSO or etoposide (10 μM) for 
up to 24 h and processed for mitochondrial membrane potential (ΔΨ) 
determination by flow cytometry. Reduced DiIC1(5) fluorescence is indicative 
of a loss of ΔΨ, and numbers refer to the percentage of cells that underwent 
a dissipation of ΔΨ.  B, duplicate aliquots of cells were harvested and 
processed for subcellular fractionation.  Supernatant (s) and pellet (p) 
fractions were analyzed by Western blotting. shRNA, short hairpin RNA; Cyt c, 
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Smac from the mitochondria (p) to the cytosol (s) that was nearly complete 
after 24 h (Figure 22B, lanes 1-5), and the Bcl-xL-and Bcl-2-overexpressing 
cell lines (Figure 22B, lanes 6-10 and 11-15, respectively) never released 
cytochrome c or Smac in the cytosol. Remarkably, despite the apparent 
absence of etoposide-induced cytochrome c release in the Apaf-1-deficient 
cells, the mitochondrial (p) pool of cytochrome c in these cells began to 
decrease by 8 h and was entirely absent from the pellet fraction at 24 h 
(Figure 22B, lanes 16-20).  Smac content also decreased from the 
mitochondrial fraction of the Apaf-1-deficient cells, although to a lesser extent. 
Combined, this suggested to us that these cells might be losing their 
mitochondrial content due to an induction of autophagy as described 
previously (Ferraro et al., 2008; Mizushima, 2007).  In addition, these data 
largely contradict the view that the mitochondria-mediated apoptotic pathway 
is a strictly linear process (Chipuk et al., 2006; Goldstein et al., 2005; 
Goldstein et al., 2000; Waterhouse et al., 2001).    
 
6.3.3 Total Cellular Cytochrome c and Smac Decreases Only in Apaf-1-
Deficient Cells 
 
Next, we wanted to rule out the possibility that the loss of cytochrome c 
and Smac in cells deficient in Apaf-1 had occurred during the process of 
subcellular fractionation.  After incubation of cells for up to 24 h with 
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etoposide, whole-cell lysate was produced for Western blot analysis.  The 
results indicated that three out of the four cell lines (vector control, Bcl-xL-and 
Bcl-2-overexpressing cells) retained all of their cytochrome c and Smac out to 
24 h with etoposide treatment (Figure 23, lanes 1-5, 6-10, & 11-15, 
respectively).  Strikingly, Apaf-1-deficient cells had lost the majority of their 
cytochrome c at 16 h and a considerable amount of Smac at 24 h post-
etoposide treatment (Figure 23, lanes 16-20).  These data confirm and extend 
the subcellular fractionation data (Figure 22B) and indicate that these cells, 
indeed, lose their cellular cytochrome c and Smac.     
 
6.3.4 Apaf-1-Deficient Cells Exhibit Biochemical Evidence of Autophagic 
Clearance of Damaged Mitochondria In Response to Etoposide 
 
In the absence of caspase activation, even proliferating cells may 
retain the ability to survive MOMP and cytochrome c release, perhaps by 
triggering autophagic clearance of “leaky” mitochondria (Boya et al., 2005).  
However, whether autophagic removal of mitochondria promotes or prevents 
cell death is controversial.  In general, if autophagy removes damaged or 
“leaky” mitochondria that could otherwise promote apoptosome-mediated 
activation of caspases, then autophagy could serve as an important pro-
survival response to stress.  A recent report showed that mitochondria that 
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Figure 23. Total Cellular Cytochrome c and Smac Levels Decrease in 
Etoposide-Treated Apaf-1-Deficient Cells. 
Vector control, Bcl-xL- and Bcl-2-overexpressing and Apaf-1-deficient Jurkat 
clones (5 X 105/ml) were cultured with DMSO or etoposide (10 μM) for up to 
24 h, harvested total cell lysate and performed Western blot analysis. β-actin 
was used as a loading control. shRNA, short hairpin RNA; Cyt c, cytochrome 
c.  
 121
caspases remain inactive and glyceraldehyde-3-phosphate dehydrogenase 
expression remains high (Colell et al., 2007). Thus, in our case, it was 
tempting to speculate that autophagic removal of damaged mitochondria 
might play a pro-survival role in cells lacking a functional apoptosome 
complex.    
Autophagy will degrade damaged cellular contents such as organelles 
or proteins (Cuervo, 2004; Klionsky, 2005, 2007; Levine and Klionsky, 2004; 
Mizushima and Klionsky, 2007; Shintani and Klionsky, 2004).  The damaged 
cellular contents are sequestered in a double-membrane vesicle called an 
autophagasome that is transported and fuses with a lysosome (Kroemer and 
Levine, 2008; Levine and Kroemer, 2008; Mizushima, 2007; Mizushima et al., 
2008). LC3-I is a 19 kDa protein that is present constitutively in the cytosol, 
whereas LC3-II is a 17 kDa protein that is bound to autophagic vesicles.   
During the production of autophagic vesicles, LC3-I is converted to LC3-II 
(Kabeya et al., 2000).  To determine if the disappearance of cytochrome c 
from the pellet fraction of Apaf-1-deficient cells (Figure 22B) might be due to 
autophagy, the disappearance of LC3-I was examined.  After 16 h of 
etoposide treatment, the Apaf-1-deficient cells lost LC3-I (Figure 24A, lanes 4 
and 5, bottom row).  These data provided some biochemical evidence that 
autophagic vesicles were being produced in the Apaf-1-deficient cells after 
long exposure with etoposide.  
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Figure 24. Apaf-1-Deficient Cells Exhibit Some Biochemical Evidence of 
Autophagic Removal of Mitochondria in Response to Etoposide 
Treatment. 
A, wild type, vector control, and Apaf-1-deficient Jurkat clones (5 x 105/ml) 
were cultured with DMSO or etoposide (10 μM) for up to 24 h, lysed and 
harvested for Western Blot analysis of LC3-I. B, Apaf-1-deficient Jurkat cells 
(5 x 105/ml) were cultured in the presence of etoposide (10 μM) for 24 h with 
or without 3-methyladenine (5 and 20 mM), lysed and harvested for Western 
blot analysis of LC3-I. C, duplicate aliquots of cells in B were lysed and 
harvested for Western blot analysis.  D, vector control or Apaf-1-deficient cells 
were cultured in the presence of etoposide (10 μM) for 24 h with or without 3-
methyladenine (5 and 20 mM), harvested and processed for subcellular 
fractionation.  Supernatant (s) and pellet (p) fractions were analyzed by 
Western blotting. shRNA, short hairpin; 3-MA, 3-methlyadenine; Cyt c, 
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If damaged mitochondria in the Apaf-1-deficient cells had been cleared by 
autophagy, then inhibiting autophagy should help retain the total cellular 
cytochrome c and Smac.  To extend this observation and to investigate the 
extent that we could inhibit the loss of LC3-I, we co-incubated cells for 24 h 
with etoposide and the autophagy inhibitor 3-methyladenine (3-MA) (Maiuri et 
al., 2007) (5 and 20 mM).  At the end of 24 h, cells were harvested and 
subjected to Western blot analysis to look for LC3-I. When compared to 
treatment with etoposide (Figure 24B, lane 2) alone, co-treatment with 3-MA 
led to the retention of LC3-I (Figure 24B, lane 3 and 4).   
Next, we were interested in determining whether co-incubation of cells 
with 3-MA would also lead to the retention of total intracellular cytochrome c 
and Smac.  Indeed, the results indicated that co-treatment of Apaf-1-deficient 
cells with 3-MA and etoposide for 24 h led to some retention of total 
intracellular cytochrome c and Smac (Figure 24C, lanes 3 and 4). More 
precisely, subcellular fractionation of cells revealed that 3-MA (20 mM) led to 
an increased mitochondrial content of cytochrome c, while Smac was retained 
at the lower concentration (5 mM) (Figure 24D, lanes 5 and 6).  Overall, these 
data suggest that at least one reason total cellular cytochrome c and Smac 
disappear in Apaf-1-deficient cells is due to autophagy.        
 
6.3.5 No Classical Autophagic Vesicles in the Apaf-1-Deficient Cells 
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Because we had observed some evidence of autophagy in etoposide-
treated Apaf-1-deficient cells, which could be inhibited partially by 3-MA, we 
next employed the gold standard for studying autophagy (i.e. electron 
microscopy) and examined cells for the presence of classical autophagic 
vesicles.  Autophagasomes can be identified by their double-membrane 
vesicles surrounding cytoplasmic organelles (Kroemer and Levine, 2008; 
Levine and Kroemer, 2008).  After treatment with etoposide for up to 24 h, 
cells were harvested, processed, and examined with a J.E.O.L 100CXII 
transition electron microscope.  Classical apoptotic morphology can be 
observed in the vector control cells after 24 h etoposide (Figure 25, top row).  
These events include chromatin condensation, maintenance of plasma 
membrane integrity, and a decrease in cytoplasmic contents.  By comparison, 
etoposide-treated Bcl-2-overexpressing cells lacked all apoptotic morphology, 
and the mitochondria appeared to be normal and intact (Figure 25 middle 
row).  Interestingly, Apaf-1-deficient cells exhibited neither classical apoptotic 
morphology nor robust autophagic vesicle formation.  Strikingly, however, it is 
important to note that the mitochondria of drug-treated Apaf-1-deficient cells 
appeared to have been damaged as evidence by their distinctly engorged or 
bloated appearance (Figure 25, bottom row). Combined, these data indicate 
that even though there are some biochemical markers of autophagy, it 
appears that autophagy is not playing the major role in the disappearance of 
cytochrome c and Smac.   
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Figure 25. No Classical Autophagic Vesicles in the Apaf-1-Deficient 
Cells Incubated in the Presence of Etoposide for 24 h. 
Vector control, Bcl-2-overexpressing, and Apaf-1-deficient Jurkat cells (5 x 
105/ml) were cultured with DMSO or etoposide (10 μM) for up to 24 h and 
harvested for examination with J.E.O.L 100CXII TEM at 80 KV.  Images were 








6.3.6 Delayed Bak Activation in Apaf-1-Deficient Cells 
 
Because autophagy could not explain the disappearance of all 
cytochrome c and Smac, we next investigated an alternative hypothesis.  We 
knew that there was no appreciable accumulation of cytochrome c and Smac 
in the cytosol.  Additionally, we knew that the mitochondria were damaged as 
indicated by the change in ΔΨ and their swollen appearance by EM.  Thus, 
we were interested to determine whether there was any evidence of MOMP 
induction in these cells.  Although we had reported previously that Bak 
activation in etoposide-treated Apaf-1-deficient cells was inhibited when 
treated for 6 h (Shawgo et al., 2008), the question arose whether Bak 
activation would remain inhibited at longer time-points.  
 Thus, we incubated cells with etoposide for 0, 4, 8, 16, or 24 h and 
harvested for Bak activation.  As reported previously, Jurkat (E6.1) cells do 
not express Bax (Shawgo et al., 2008).  After treatment, cells were incubated 
with BMH, a protein cross-linker, and subjected to Western blot analysis.  As 
mentioned earlier, Bak activation is associated with its homo-oligomerization.  
Both the Bcl-xL-and Bcl-2-overexpressing cells never activated Bak, whereas 
vector control cells began activating Bak as early as 4 h after etoposide-
treatment (Figure 26).   Interestingly, Apaf-1-deficient cells were found to 
activate Bak beginning at 8 h post-treatment; however, the extent to which  
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Figure 26. Delayed Bak Activation in Apaf-1-Deficient Cells After 
Treatment With Etoposide. 
Vector control, Bcl-xL- and Bcl-2-overexpressing, and Apaf-1-deficient Jurkat 
cells (5 x 105/ml) were cultured with DMSO or etoposide (10 μM) for up to 24 
h and processed for determination of Bak oligermerization by Western blotting. 
shRNA, short hairpin RNA; BMH, bismaleimidohexane. 
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Bak was activated in cells lacking Apaf-1 was always less than that observed 
in vector control cells (Figure 26 lane 20 versus 5).  Overall, these data 
indicate that etoposide-induced Bak activation is delayed, but not prevented, 
in the Apaf-1-deficient cells.  Further, the fact that Bak was activated 
suggested that the mitochondrial outer membrane had been permeabilized to 
some extent and that the mitochondria are indeed damaged.            
 
6.3.7 Inhibition of the 26S Proteasome Prevents the Loss of Cytochrome c 
and Smac in the Apaf-1-Deficient Cells 
 
Since mitochondria in the Apaf-1-deficient cells appeared to have been 
permeabilized after longer exposures to etoposide, we hypothesized that pro-
apoptotic factors were being released into the cytosol and rapidly degraded, 
perhaps by the 26S proteasome.  To investigate this possibility, Apaf-1-
deficient cells were co-treated with bortezomib (10, 20, 40 nM), an inhibitor of 
the 26S proteasome, and etoposide.  Cells were then harvested for 
determination of total cellular cytochrome c and Smac levels. Compared to 
treatment with etoposide alone (Figure 27A, lane 2), co-treating with 
bortezomib led to a retention of cellular cytochrome c and Smac.  
Subsequently, we were curious to know in which subcellular compartment(s) 
bortezomib would lead to an increased cytochrome c and Smac content.  The 
results indicated that cytochrome c and Smac were retained in both the  
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Figure 27. Inhibition of the 26S Proteasome Prevents the Loss of 
Cytochrome c and Smac in Etoposide-Treated Apaf-1-Deficient cells. 
A, Apaf-1-deficient Jurkat clones (5 x 105/ml) were cultured with etoposide 
(10 μM) with and without bortezomib (10, 20, 40 nM) for 24 h, and harvested 
for Western blot analysis. B, vector control cells were treated with etoposide 
(10 μM) for 24 h and duplicate samples in A were harvested for subcellular 
fractionation.  Supernatant (s) and pellet (p) fractions were analyzed by 
Western blotting. C, Apaf-1-deficient Jurkat clones (5 x 105/ml) were cultured 
with etoposide (10 μM) with and without MG132 (0.5, 1, 5 nM) for 24 h, and 
harvested for Western blot analysis.  β-actin was used as a loading control.  
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cytosol and mitochondrial fractions; however, Smac was retained to a greater 
extent than cytochrome c in the mitochondrial fraction (Figure 27B).  
Importantly, these findings were confirmed using another 26S proteasome 
inhibitor, MG132.  Indeed, co-incubation of Apaf-1-deficient cells with MG132 
(0.5, 1, 5 nM) and etoposide for 24 h led to the retention of intracellular 
cytochrome c and Smac in a concentration-dependent manner (Figure 27C).  
Combined, these data suggest that cytochrome c and Smac are released 
from mitochondria and degraded by the 26S proteasome in etoposide-treated 
Apaf-1-deficient cells. 
          
6.4 Concluding Remarks  
 
In summary, all the gene-manipulated cells were similarly resistant to 
etoposide up to 24 h evaluated by annexin/PI staining.  However, only the 
Apaf-1-deficient cells exhibited some evidence of caspase activation after 24 
h of etoposide treatment.  Secondly, the Apaf-1-deficient cells appeared to 
have a modest change in ΔΨ observed by staining with DilC1(5).  The change 
in ΔΨ led us to discover that total intracellular cytochrome c and Smac 
disappear from Apaf-1-deficient cells after treatment with etoposide for 16 - 
24 h. When autophagy was explored as a possible mechanism for their 
disappearance, subtle biochemical evidence was observed but no gross 
appearance of classical autophagic vesicles could be detected.  Otherwise, 
 134
the delayed Bak activation that was observed suggested that pro-apoptotic 
proteins could possibly be released into the cytosol.  Indeed, the findings 
indicated that once cytochrome c and Smac were released into the cytosol in 
cells deficient in Apaf-1, they were rapidly degraded by the 26S proteasome.  
Combined, these data suggest that proteasomal degradation, and to a lesser 
extent autophagic removal of mitochondria, are responsible for the loss of 
intracellular cytochrome c and Smac in Apaf-1-deficient cells incubated with 
etoposide over extended time periods.  
 These findings are consistent with an emerging model of the intrinsic 
pathway in which after a cell’s DNA becomes damaged, a small amount of 
Bak (or Bax) activation occurs, by a still poorly defined mechanism, to release 
a small amount of apoptogenic proteins into the cytosol.  These pro-apoptotic 
factors will then help to activate caspases both directly (cytochrome c) and 
indirectly (Smac).  To the extent this results in the activation of effector 
caspases, Bid can be cleaved to tBid to promote additional activation of Bak 
(or Bax) and the release of more apoptogenic proteins.  This forms the basis 
of an essential feed forward loop among effector caspases, Bid, and the 
mitochondrial outer membrane.  In the case of Apaf-1 deficiency, the initial 
release of cytochrome c would seem to serve no purpose since it cannot 
promote the activation of caspase-9 within the apoptosome complex.  
Likewise, there is no activated caspase-3, -7 or -9 that is being held up by an 
inhibitor of apoptosis protein for Smac to bind and thereby neutralize.  In 
 135
instances where the release of cytochrome c and Smac do not result in the 
activation of caspases, our findings suggest that these pro-apoptotic factors 
present in the cytosol are mostly degraded by the 26S proteasome, and less 
so by a mechanism involving autophagic removal of damaged mitochondria.  
Overall, it is tempting to speculate that the degradation of these pro-apoptotic 
proteins might serve as a protective mechanism against inadvertent apoptosis 
induction.      
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 How the New Conclusions Impact Controversies in the Field and Future 
Directions 
 
It was once thought that mitochondria-mediated apoptosis involved 
only a few linear steps.  In response to an apoptotic stimulus, the 
mitochondria would be permeablized to allow activation of caspases to cause 
cell death.  However, as investigators have studied the molecular 
requirements and mechanisms of apoptosis, we now know that apoptotic 
signaling is not so straightforward.  For example, considerable controversy 
persists over the precise mechanisms responsible for MOMP.  Some of the 
unresolved questions that persist include: (i) Once one mitochondrion in a cell 
has its released pro-apoptotic proteins, do all the mitochondria in the cell 
release their pro-apoptotic factors? (ii) Are the different pro-apoptotic factors 
released simultaneously? (iii) What is considered to be the point of no return? 
(iv) Are there two waves of release of pro-apoptotic factors?   The results of 
my dissertation research contribute toward the resolution of some of these 
questions.   
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7.1.1 Once One Mitochondrion in a Cell has Released Pro-Apoptotic Proteins 
Do All the Mitochondria in the Cell Release Their Pro-Apoptotic Proteins? 
 
Some controversies in the field are how quickly do pro-apoptotic 
proteins get released into the cytosol and does one mitochondrion releasing 
its pro-apoptotic factors cause other mitochondria to release their pro-
apoptotic factors.  Much in the literature argues that if one of these pro-
apoptotic factors is released, all of the pro-apoptotic proteins are released 
from all mitochondria.  For instance, using GFP-labeled cytochrome c, it was 
shown that within 5 min all cytochrome c had been released in response to 
UV radiation, staurosporine, actinomycin D, or etoposide.  This is where the 
“all or none” theory of MOMP was initially proposed (Goldstein et al., 2005; 
Goldstein et al., 2000).  This theory was expanded to suggest that 
cytochrome c release can cause the release of cytochrome c from other 
mitochondria  (Kagan et al., 2004).   However, other studies have suggested 
that when one mitochondrion releases its pro-apoptotic factors, it does not 
affect the release by the neighboring mitochondria (Khodjakov et al., 2004; 
Lartigue et al., 2008).  Zhou and Chang suggest that unlike cytochrome c that 
is all released at once, Smac is not released all at once  (Zhou and Chang, 
2008; Zhou et al., 2005).  Lartigue et al. even suggested that cytochrome c 
release happens before Bax activation (Lartigue et al., 2008).  We show that 
cytochrome c release is not instantaneous (Figure 13B, 15B and 21B).  If 
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cytochrome c was released in an all-or-none manner, then inhibiting 
“downstream” events such as apoptosome formation (Figures 12 and 13) 
and/or the activation of effector caspases (Figures 14 and 15) would not have 
influenced the release of pro-apoptotic factors (Shawgo et al., 2008).  
Inhibition of “downstream” events that then inhibit “upstream events,” such as 
MOMP, points to the existence of an essential feed forward loop.   A feedback 
loop has also been suggested by a few groups (Boehning et al., 2003; 
Kroemer et al., 2007; Lartigue et al., 2008; Pacher and Hajnoczky, 2001).  We 
show that effector caspase activation is required for the cleavage of Bid to 
tBid to feed forward and activate more Bak (Shelton et al., 2009).  The 
release of pro-apoptotic factors not being an all-or-none event was further 
supported when we incubated our Apaf-1-deficient cells long-term with 
etoposide.  Specifically, a slow time-dependent release of cytochrome c and 
Smac from mitochondria was observed as evidence by the disappearance of 
cytochrome c and Smac in the mitochondrial fraction (Figure 22B).  In 
conclusion, our data suggest that the release of pro-apoptotic factors is not a 
rapid singular event.  It is a process that occurs after “downstream events” 
(i.e., effector caspase activation) have occurred.  These “downstream events” 
are essential for the complete release of pro-apoptotic proteins from the 




7.1.2 Are the Different Pro-Apoptotic Factors Released All Together?  
 
Whether or not different pro-apoptotic factors are released at the same 
time is a second controversy in the field.  That is, when cytochrome c is 
released do other pro-apoptotic factors such as Smac get released?  The 
majority of the literature suggests that pro-apoptotic factors are released 
together.  For example, it has been suggested that Smac and Omi are 
released at the same time as cytochrome c (Kashkar et al., 2002; Munoz-
Pinedo et al., 2006; Twiddy et al., 2004).  However, it has also been shown 
that cytochrome c-null cells do not release Smac after treatment with the 
DNA-damaging drug etoposide (Hansen et al., 2006).   
Our data also suggest that when pro-apoptotic factors are released 
into the cytosol, their release into the cytosol is at least partially independent 
of each other.  We first made the observation that Apaf-1-deficient cells are 
inhibited in their release of cytochrome c in response to etoposide.  However, 
Smac release was not inhibited to the same extent that cytochrome c release 
was inhibited (Franklin and Robertson, 2007; Shawgo et al., 2008).  This 
difference was extended when we incubated cells with etoposide for periods 
longer than 6 h (Figure 22B).  We also saw a difference between the inhibition 
of cytochrome c and Smac release when we inhibited caspase activation by 
overexpressing XIAP and XIAP’s BIR1/BIR2 domains (Figure 15B).  This 
suggests that there may be a difference in their release and in the future this 
idea could be explored more.  
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7.1.3 What is Considered to Be the “Point of No Return”?  
 
What is the “point of no return” during mitochondria-mediated 
apoptosis?  Many researchers believe that MOMP is the “point of no return” 
within the intrinsic pathway, meaning that the cells are unable to recover once 
MOMP has occurred (Green and Kroemer, 2004; Kroemer and Reed, 2000).   
Apoptosome formation (Apaf-1, cytochrome c, dATP, pro-caspase-9) is 
widely thought to occur strictly downstream of MOMP.  However, Franklin and 
Robertson (2007) recently reported that Apaf-1-deficient Jurkat T-
lymphocytes fail to release pro-apoptotic factors into the cytosol in response 
to the DNA-damaging anti-cancer drug etoposide.  It was also demonstrated 
that “downstream events” such as effector caspase activation (Figure 15; 
(Shawgo et al., 2008)) and Bid cleavage (Shelton et al., 2009) were required 
for full activation of MOMP and to allow the cell to undergo apoptosis.  
Additionally, when we extended the treatment of the Apaf-1-deficient cells out 
to 24 h, MOMP did occur; however, the cell did not undergo apoptosis (Figure 
22B).  These data suggest that MOMP is not the point of no return.  However, 
it is very tempting to speculate that there is a threshold to how many pro-
apoptotic proteins need to be released and how much effector caspase 
activation is required before the cell is irreversibly committed to apoptosis.  
Basic biochemical subcellular experiments will have to be done to determine 
exactly what that threshold is. 
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7.1.4 Are There Two Waves of Release of Pro-Apoptotic Factors? 
 
If the release of pro-apoptotic factors is not instantaneous and MOMP 
is not the “point of no return” then there could be multiple waves of pro-
apoptotic factors being released from the mitochondria into the cytosol.  
Those that do believe in multiple waves of pro-apoptotic protein release might 
examine the underlying mechanism(s).  The redundancy of the function of 
Bak and Bax has been disputed for a long time.  Originally, it was suggested 
that Bak and Bax have redundant roles because only double knockout mice 
are totally protected against various forms of mitochondria-mediated 
apoptosis (Wei et al., 2001; Youle and Karbowski, 2005).  Single knockout 
mice show only partial protection from apoptosis.  However, one obvious 
difference between Bax and Bak is their intracellular location.  Bax is normally 
present in the cytosol, whereas Bak is loosely associated with the 
mitochondrial outer membrane.  Indeed, it is now appreciated that Bax has to 
translocate to the mitochondria, insert into its outer membrane, and form a 
pore for the release of pro-apoptotic factors into the cytosol, while Bak just 
has to form a pore.  Many consider the activation of Bax as occurring in one 
quick step (Antonsson et al., 2000; Antonsson et al., 2001; Gross et al., 1998; 
Saito et al., 2000; Wang et al., 1998).  However, more recently these events 
have been shown to occur in multiple steps that can take some time (minutes- 
hours).  To ensure that previous experimental procedures (use of certain 
detergents) have not interfered with the endogenous native form of Bax, one 
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study used a blue native page gel to show that there is another level of 
regulation of Bax activation.  Bax first has to translocate to the outer 
mitochondrial membrane, oligomerize, and then subsequently become 
activated (Valentijn and Gilmore, 2004).  This suggests that translocation or 
oligomerization does not mean that Bax is necessarily active.  Unfortunately, 
they did not look at Bak in detail.  Thus, there could be another unknown level 
of regulation to Bak activation to help explain what occurs during the essential 
feed forward amplification loop.  The level of Bax/Bak redundancy was 
challenged by the work of Cheng et al. who demonstrated that Bak, but not 
Bax, co-immunoprecipitated with VDAC2 (Cheng et al., 2003; Upreti et al., 
2008).  Additionally, studies have demonstrated that Bak+/Bax- are more 
sensitive to apoptotic stimuli than Bak-/Bax+ MEFs (Upreti et al., 2008).  There 
is also controversy whether or not Bak and Bax hetero-oligomerize.  There 
are a few groups that suggest that homo-oligomerized Bak and Bax can 
hetero-oligomerize to form larger complexes (Upreti et al., 2008; Zhou and 
Chang, 2008). If there are differences in the roles of Bax and Bak in MOMP, 
this could help explain how a biphasic release of pro-apoptotic factors takes 
place and could be investigated in the future.  Perhaps, there is an initial 
release of pro-apoptotic factors that homo-oligomerize and then the major 
release occurs due to hetero-oligermerization of Bax and Bak.  It is worth 
noting again that our Jurkat cells do not express Bax (Figure 13C).  In the 
case of our data, the dramatic result of MOMP inhibition could be due to the 
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inability of our cells to make those hetero-oligermerized complexes.  In 
conclusion, our data would suggest that there is a small release of pro-
apoptotic factors into the cytosol that allows activation of effector caspases to 
feed forward to activate more Bak to release more pro-apoptotic factors.  
However, the exact amount of pro-apoptotic factors that are released initially 
versus how much is due to the feed forward amplification loop is not known 
and could be explored in the future.   Determining the mechanism of the 
biphasic release of pro-apoptotic factors could also contribute to the 
understanding of how much of the pro-apoptotic players are needed to 
commit the cell to die.   
 
7.2 Caspase-Mediated Bak Activation and Cytochrome c Release During 
Intrinsic Apoptotic Cell Death in Jurkat Cells 
 
 Overall our data support the hypothesis of a non-linear pathway for 
mitochondria-mediated apoptosis (Figure 28).  We suggest that the 
commitment of a cell to undergo apoptosis depends on caspases and 
mitochondria forming an essential amplification circuit that functions as a 
central control point of genotoxic stress-induced apoptosis.   After the 
apoptotic stimulus of DNA damage, mitochondria-mediated apoptosis is 
initiated.  Initially, a small amount of a Bcl-2 multidomain pro-apoptotic protein 
























Figure 28. Feed Forward Perspective. 
Caspases and mitochondria form an essential amplification circuit that 
functions as a central control point of genotoxic stress-induced apoptosis. Cyt 
c, cytochrome c; tBid, truncated Bid; Casp, caspase; IAP, inhibitor of 
apoptosis proteins; Bid, BH3 interacting domain; Apaf-1, apoptotic protease 
activating factor 1; Bak, Bcl-2 antagonist/killer 1; Bax, Bcl-2-associated X 
protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, Bcl-2 like 1.
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the first pass through the mitochondria-mediated pathway to occur.  
Specifically, a small amount of pro-apoptotic factors (cytochrome c and 
Smac) are released into the cytosol.  This allows for a few initiator caspase-9 
molecules to become activated.  These activated caspase-9 proteases, in 
turn, can cleave and activate caspase-3 to an extent that is sufficient to 
cleave Bid.  The Bid that is cleaved allows for more Bak activation and thus 
causes a second more productive pass through the mitochondria-mediated 
pathway and so on.  In other words, it is like the repeated passing of a roller 
coaster on a rail.  If, the first time, the train of cars is almost empty, the lower 
weight will cause a lower maximum speed.  If some more people jump in as 
the train passes through the station, the second time around with more weight 
the speed will increase.  In a similar way, each time the cell releases more 
pro-apoptotic factors into the cytosol, the speed and extent to which the cell is 
degraded will increase.     
 
7.3 Caspase-9 Activation by the Apoptosome Is Not Required for Fas-
Mediated Apoptosis in Type II Jurkat Cells 
 
It has been widely asserted that for a type II cell to undergo receptor-
mediated apoptosis that it needs the mitochondria-mediated pathway to 
amplify the amount of caspase-3 activation that occurs initially.  This is due to 
the low caspase-8 activation at the DISC in a type II cell.  Caspase-8 
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activation in a type II cell is insufficient to cleave enough caspase-3 to cause 
cell death.  However, what was less understood was what part of the 
mitochondria-mediated pathway was actually required to increase caspase-3 
activation.  We demonstrated by eliminating apoptosome-mediated activation 
of caspase-9 that what was needed from the mitochondria-mediated pathway 
was the release of Smac, not cytochrome c.  Under normal conditions, as a 
way to protect the cell from accidental partial activation of caspases, IAPs 
reside in the cytosol waiting to sequester any inadvertantly activated 
caspases.  There is a balance between how many activated caspases and 
how many IAPs are present.  If a cell can activate enough caspases, then 
they can overcome the inhibition, but when they cannot, IAP will prevent cell 
death.  In other instances, however, there is another level of complexity.  
Specifically, in type II cells, where initial caspase-8 activation is too low to 
induce cell death, Smac and/or Omi protein(s) need to be present to inhibit 
IAPs and promote cell death.  In this case, after the stimulation of the 
receptor-mediated pathway, the low amount of caspase-3 activation that did 
occur was all inhibited by IAPs.  Smac and Omi must be released into the 
cytosol to inhibit IAPs.  This releases the activated caspase-3 to not only 
dismantle the cell, but also activate the feed forward amplification circuit that 
was described earlier.       
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7.4 Apaf-1 Deficiency Promotes the Elimination of Cytochrome c and Smac 
by Proteasomal Degradation, and to a Lesser Extent Autophagy, in Response 
to Genotoxic Stress 
 
It would seem that the cell has developed another way to help protect 
itself from accidental apoptosis.  A cell requires considerable energy to 
produce itself and presumably would want to be certain before committing 
itself to die, while reserving the ability to die if it cannot repair or recover from 
a given injury.  This is evident when one considers the complexity of apoptotic 
regulation.  Specifically, not only do apoptotic proteins regulate each other via 
protein-protein interactions (e.g. anti-apoptotic Bcl-2 family members inhibit 
pro-apoptotic Bcl-2 family members) but most apoptosis proteins are also 
internally regulated (i.e. post-translational modifications of Bid being cleaved 
to activate tBid).  It is also clear that other cellular processes can be involved 
in regulation of apoptosis (i.e. increased transcription or translation).   For 
example, up-regulation of Puma (p53-dependent pro-apoptotic Bcl-2 family 
member) has been reported during some forms of genotoxic stress-induced 
apoptosis.   
My results also implicate another way in which a cell can protect itself 
from accidental apoptosis.  A cell limits the length of time a pro-apoptotic 
factor released from the mitochondria can be retained in the cytosol.  This 
time limit occurs when the cell is not actively undergoing apoptosis.  This was 
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observed in the Apaf-1-deficient cells after prolonged incubation with the 
DNA-damaging drug etoposide.  The initial amount of pro-apoptotic factors 
that were released into the cytosol in cells lacking Apaf-1, after being 
damaged with etoposide, have no purpose since caspase activation did not 
ensue.  In this case, my data suggested that the released pro-apoptotic 
proteins are continuously degraded within the 26S proteasome (Figure 27).   
Lastly, another cellular process that can help protect the cell after an insult is 
autophagy.  After prolonged incubation with etoposide total cellular 
cytochrome c and Smac disappeared in the Apaf-1-deficient cells.  We see a 
partial retention of cytochrome c and Smac with autophagy inhibitors.  These 
data suggest that autophagic removal of damaged mitochondria may play an 
important pro-survival role in eliminating damaged mitochondria after 
apoptotic stimuli.   
 
7.5 Concluding Remarks 
 
 
In conclusion, the mitochondrial pathway appears to not proceed in a 
strictly linear fashion after treatment with the DNA-damaging drug etoposide.  
What was once considered “downstream events”, such as caspase activation 
is now required for etoposide-induced mitochondrial apoptotic events.  It 
appears that only the release of IAP antagonists are required from the 
mitochondria-mediated pathway after stimulation of a death receptor.  The 
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apoptotic pathways are more complex than once thought.  It is this “checks 
and balances” system that allows the body to be the most energetically 
proficient and ultimately determines if the cell will live or die.  This new 
information about the process of MOMP presented in my dissertation 
provides important information that may help in drug development in the 
future. 
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